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Abstract 
 Protein folding in the endoplasmic reticulum (ER) is error-prone, and ER 
quality control processes exist (ERQC) to ensure only correctly folded proteins 
are exported from the ER en route to the Golgi compartment.  Glycoproteins with 
amino acid mutations can be retained in the ER by ERQC, and this retention 
contributes to multiple human diseases, termed ER storage diseases.  UDP-
glucose:glycoprotein glucosyltransferase (UGGT1, GT1) is proposed to be a 
central component of ER glycoprotein quality control.  The mechanism of 
UGGT1-mediated monoglucosylation of deglucosylated N-glycans of 
incompletely folded glycoproteins, and the subsequent reassociation of these 
glycoproteins with lectin-like chaperones (calreticulin and calnexin) in the ER has 
been extensively described.  However, the extent to which UGGT1 influences the 
folding of ER substrate proteins has only been investigated for a few selected 
substrates.  Using mouse embryonic fibroblasts lacking UGGT1, or those with 
UGGT1 complementation, we investigated the effect of monoglucosylation on the 
soluble/insoluble distribution of two misfolded alpha-1 antitrypsin (AAT) variants 
responsible for AAT deficiency disease, null Hong Kong (NHK) and Z allele 
(ATZ).  Our results indicate that, whereas substrate solubility increases directly 
with the number of N-linked glycosylation sites, additional solubility is conferred 
by UGGT1 enzymatic activity at the expense of the pool of insoluble protein 
complexes in the ER.  Monoglucosylation-dependent solubility decreases both 
BiP association with NHK and unfolded protein response (UPR) activation, and 
the solubility increase is blocked in cells deficient for calreticulin.  These results 
suggest that UGGT1-dependent monoglucosylation of N-linked glycoproteins 
promotes substrate solubility in the ER.
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Chapter 1 
Introduction 
 
1.1 Introduction 
  
Over the past thirty years, multiple human genetic diseases have been 
identified where pathogenesis is directly linked to endoplasmic reticulum (ER) 
retention of misfolded glycoproteins, sometimes with mutation as modest as a 
single amino acid substitution[1].  These diseases have been termed ER storage 
diseases[2].  Interestingly, many of these mutant glycoproteins still possess the 
biological activity of their wild-type counterparts, as demonstrated by experiments 
in which a functional product is exported under conditions of altered temperature, 
or after treatment with chemical chaperones[3, 4].  The process whereby 
imperfectly-folded proteins are retained in the ER, and proteins with a native fold 
are permitted export from the ER, has been termed ER quality control (ERQC)[5].  
In some instances, the pathogenicity associated with the expression of mutant 
glycoproteins might be reduced if ERQC were to be altered.  Accordingly, much 
research effort has been directed toward understanding the mechanism of 
ERQC, with the goal of finding ways to usher problematic glycoproteins past the 
ERQC barrier without disrupting generalized ER function[6]. 
Glycosylation has been described as the most common post-translational 
modification of proteins[7], with a majority of glycoproteins bearing covalent 
attachment of oligosaccharide to asparagine side-chains (N-linked glycosylation).  
These oligosaccharides, termed N-linked glycans or simply N-glycans, are added 
in the ER where they serve as an entry pass to an intricate glycoprotein-specific 
portion of the ERQC system that ultimately enhances the export efficiency of high 
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quality glycoprotein products[8].  In overview, glycoprotein-specific ERQC 
functions through a multitude of proteins: sugar-modifying enzymes, sugar-
binding lectins, and protein-binding chaperones.  The N-glycans are trimmed 
during glycoprotein folding, and the various trimmed glycans facilitate recognition 
of substrate glycoproteins by various QC factors.  This chapter highlights the 
mechanisms and principles of glycoprotein-specific ERQC, beginning with an 
introduction to general ERQC and implications for cell stress responses.  Then, 
to focus on glycoprotein ERQC, I address the addition of N-linked 
oligosaccharides to nascent polypeptides, then shift to the cyclical 
deglucosylation and reglucosylation of N-glycans, and finally end with 
consideration of ER exit, retention, degradation, or accumulation of insoluble 
glycoprotein secretory products. 
 
1.2  Protein folding, ER stress and the unfolded protein response (UPR) 
 
The discovery of molecular chaperones in distinct cellular compartments 
challenged the concept that proteins fold spontaneously according to their amino 
acid sequence and length.  Molecular chaperones are required for correct folding 
and assembly of proteins, and form the basis for the ‘assisted folding hypothesis’ 
[9, 10]. Experiments showed chaperones could also promote correct protein 
folding by reducing the propensity of proteins to aggregate both in vitro and in 
cells[9].  Mechanistically, interactions with chaperones may: 1) improve kinetics 
of appearance of functional conformation, or 2) prevent formation of incorrectly 
folded structures[9].  Proteins tend to aggregate because transiently exposed 
hydrophobic side-chains that normally form weak intramolecular bonds form 
weak intermolecular bonds with an adjacent molecule.  This disrupts the native 
state of the attacked molecule, exposing hydrophobic residues that normally 
would not be exposed, and the chain reaction continues[10], unless molecular 
chaperones bind the exposed hydrophobic residues. 
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Generally, proteins recognized as unfolded by molecular chaperones are 
retained in the ER[11].  This can produce a situation where the amount of 
unfolded protein in the ER exceeds the folding capacity of the ER.  This situation 
is known as ER stress[12], which triggers an ER stress response also known as 
the unfolded protein response (UPR)[13].  The acute UPR is an adaptive 
response to resolve and limit protein misfolding. Very briefly, the UPR utilizes 
three transmembrane signal transducers to reduce the amount of misfolded 
protein in the ER by two main mechanisms.  First, mRNA translation is 
decreased globally—limiting entry of newly-synthesized proteins into an 
incapacitated ER protein folding environment—through phosphorylation of the 
alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) by the ER-
localized transmembrane UPR signal transducer PERK.  Second, UPR 
upregulates transcription of genes encoding protein translocation, folding, 
trafficking and degradative functions, to reduce misfolded protein accumulation 
through: 1) trafficking and cleavage-activation of ATF6, 2) IRE1-initiated 
unconventional splicing of XBP1 mRNA, and 3) phospho-eIF2alpha stimulated 
translation of ATF4[13].  Importantly, expression of many proteins involved in 
ERQC is increased by the UPR, highlighting the connection between ER stress 
and ERQC[13, 14]. 
BiP (immunoglobulin binding protein) is an HSP70 family member and  
molecular chaperone that is highly expressed in the ER[15].  Binding assays on 
random peptide libraries demonstrated that short hydrophobic peptides 
preferentially bound to BiP[15].  These and other studies led to the conclusion 
that BiP binds unfolded proteins in the ER[12].  BiP binding to unfolded proteins 
also involves an ADP-ATP cycle, where the ADP-bound BiP form has a high 
affinity for bound protein, and an exchange of ATP for ADP releases the 
substrate from BiP[12].  Since BiP binds unfolded but not correctly folded 
proteins, it acts as a quality control factor in the ER, retaining unfolded protein 
forms that have not yet reached a folding form that allows for ER exit[12].   
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Along with the BiP-based chaperone system, there is also a glycoprotein 
specific chaperone system termed the ‘calnexin cycle’, which involves the lectin-
like chaperones calnexin (CNX) and calreticulin (CRT), and the glycan-modifying 
enzymes glucosidase II (GSII) and UDP-glucose:glycoprotein glucosyltransferase 
(UGGT1).  These two chaperone systems can act on the same substrate, and 
can act as complementary ERQC systems if substrate interaction with BiP or 
CRT/CNX is impeded[16-18].  Before describing in depth the glycoprotein-
specific calnexin cycle ERQC system, I will first describe the initial formation and 
processing of glycoproteins in the ER.       
 
1.3  N-linked glycoprotein processing in the ER 
 
1.3.1  Oligosaccharide formation and transfer to nascent polypeptides 
 
N-linked oligosaccharide addition and processing begins with assembly of 
a tetradecaoligosaccharide core.  Construction of the glucose3mannose9N-
acetylglucosamine2 (Glc3Man9GlcNAc2) oligosaccharide begins and ends on a 
dolichyl pyrophosphate molecule anchored in the ER membrane.  Multiple 
glycosyltransferases and sugar donors coordinate the step-wise assembly of the 
oligosaccharide, which initiates on the cytoplasmic face of the ER to produce 
Man5GlcNAc2, and is completed on the luminal side of the ER membrane[19].  
The Glc3Man9GlcNAc2 is a triantennary structure having three mannose chains 
(A, B, and C, SEE FIGURE 1.1) with three glucose residues attached to the A 
chain[20].  The end result of this process is a fully-formed dolichyl 
pyrophosphate-linked Glc3Man9GlcNAc2 oligosaccharide on the luminal side of 
the ER membrane, ready to be used as a substrate for N-linked protein 
glycosylation[21]. 
Glc3Man9GlcNAc2 oligosaccharides are transferred to nascent 
polypeptides by oligosaccharyltransferase (OST). The mammalian 
oligosaccharyltransferase (OST) exists as multiple isoforms, with multiple distinct 
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subunits.  One subunit, STT3, plays a critical catalytic role in OST function[21, 
22].  OST isoforms containing either of two STT3 subunits (STT3-A or STT3-B) 
have been identified, and have differences in both tissue distribution and 
enzymatic activity.  OST isoforms containing STT3-B are much more active and 
less discriminating of donor sugar forms, transferring non-canonical 
Man9GlcNAc2 oligosaccharides at a higher rate than STT3-A containing 
isoforms[23].  Other mammalian OST subunits include ribophorin I, ribophorin II, 
OST48, DAD1, and keratinocyte-associated protein 2 (KCP2), and depletion of 
these subunits can have deleterious effects on OST stability and function[24, 25]. 
Glc3Man9GlcNAc2 oligosaccharides are transferred cotranslationally to 
newly-synthesized glycoproteins as they are translocated into the ER lumen[26, 
27].  The oligosaccharide is transferred to an acceptor Asn (Figure 1.1), in the 
context of the N-linked glycosylation sequon, Asn-X-Ser/Thr (where X can be any 
amino acid except proline)[28].  Transfer generally occurs when the acceptor Asn 
residue is 12-14 residues away from the ER membrane[29].  Recently, the 
structure for a bacterial OST was solved, and this structure illuminates the 
mechanism of N-linked glycosylation at the molecular level[30].  The peptide and 
lipid-linked oligosaccharide binding sites are on opposite sides of the OST, and 
there is a tunnel through which the acceptor Asn can contact the lipid-linked 
oligosaccharide to form the N-glycosidic bond[30].  Interestingly, post-
translocational N-glycosylation of proteins retained in the ER has been reported, 
so N-glycosylation may not be strictly a cotranslocational event, although the 
majority of N-glycosylation does occur cotranslocationally[31, 32].  
Not every potential N-glycosylation site receives an oligosaccharide, and 
regulation of N-glycosylation occupancy could serve as an early step affecting 
glycoprotein ERQC.  In a recent study of the mouse N-glycoproteome, brain 
tissue was found to have a high rate of N-glycosylation site occupancy, with less 
than 2% of potentially glycosylated peptides detected in unglycosylated 
states[33].  This same study also showed that about half of the identified 
glycoproteins only had one N-glycan, and that mouse brain glycoproteins had the 
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highest amount of N-glycosylation per glycoprotein, when compared to kidney, 
liver and heart[33].   
The cellular consequences of blockade of N-glycan addition have been 
studied using tunicamycin (TM), a nucleoside antibiotic which blocks the first step 
in N-linked oligosaccharide assembly, transfer of GlcNAc-1-P from UDP-GlcNAc 
to dolichyl-P by GlcNAc-1-P transferase[34].  When invertase from 
Saccharomyces cerevisiae was expressed heterologously in Xenopus laevis 
oocytes, complete blockade of N-glycosylation (by TM) treatment increased ER 
retention of invertase, significantly reducing the amount secreted – but the non-
glycosylated secreted invertase still retained activity[8].  These studies indicate 
that inhibiting initial glycan addition to N-linked glycoproteins can significantly 
affect glycoprotein export from the ER, but does not necessarily preclude 
formation of biologically active products.  However, in most instances, TM 
treatment does in fact trigger massive misfolding and accumulation of 
unglycosylated versions of glycoproteins in the ER, leading to ER stress[13, 35-
37]. In many cases these misfolded proteins are bound to the protein chaperone 
BiP[12]. 
Our understanding of the biological roles of N-glycans in protein function, 
including roles in protein targeting, cell signaling and trafficking, and immune 
response, has been steadily increasing.  Mutations in many of the steps of N-
linked glycan biosynthesis and processing lead to devastating (often fatal) 
‘congenital disorders of glycosylation’ (CDGs), highlighting the widespread 
importance of this common post-translational modification[19].  Among the most 
important molecular effects are the biophysical consequences of N-glycan 
addition to substrate glycoproteins in the ER.  On the one hand, studies 
comparing thermal stability of purified glycoproteins to their unglycosylated 
counterparts produced in vitro through enzymatic deglycosylation probably do not 
accurately reflect these consequences, because N-glycans are rapidly processed 
to diverse forms through the action of ER and Golgi glycosidases and 
glycosyltransferases[38].  On the other hand, Schulke et al. compared the in vitro 
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thermal stability of glycosylated and non-glycosylated yeast invertase whose N-
glycan forms remain of a high-mannose type throughout protein maturation; 
although the effect of glycosylation on thermal stability was somewhat minor[39], 
the major biophysical effect was that the non-glycosylated form was more 
susceptible to protein aggregation[40].  Although those studies did not specifically 
consider the contributions of glycoprotein ERQC, additional cellular studies 
revealed that blockade of N-glycan addition not only blocked invertase 
secretion[41] but also resulted in the protein acquiring an abnormally trypsin-
resistant state[42] typically seen for insoluble protein complexes[43, 44].  Thus, 
existing data suggest that a common biophysical consequence of N-glycosylation 
of substrate glycoproteins in the ER is enhanced folding/solubility. 
 
1.3.2  Processing of Glc3Man9GlcNAc2 to Glc1Man9GlcNAc2 
 
 It has been known for more than thirty years that after Glc3Man9GlcNAc2 is 
added en bloc to proteins in the ER, the outermost glucose molecule is cleaved 
almost immediately by glucosidase I (GS1), forming Glc2Man9GlcNAc2[45].  GS1 
is an integral membrane glycoprotein that cleaves the (alpha1,2)-glycosidic 
linkage between the terminal and middle glucose on Glc3Man9GlcNAc2 N-
glycans.  GS1 is notable as being the enzyme deficient in congenital disorder of 
glycosylation type IIb (CDG-IIb)[46, 47].  The index patient with CDG-IIb was a 
compound heterozygote for two different GS1 missense mutations with 
enzymatic analysis (of liver tissue and skin fibroblasts) demonstrating an almost 
complete lack of GS1 activity.  That patient survived embryonic development but 
did not live beyond 2.5 months of age, with multiple organ system failure 
including severe neurological defects (hypotonia, hypoventilation and seizures), 
dysmorphic features, and progressive hepatomegaly[47].  Thus, GS1 appears 
essential for postnatal human life.   
GS1-mediated glucose trimming prevents re-binding of the processed N-
glycan by OST[48] and also promotes recognition by a recently discovered 
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membrane-anchored ER protein called malectin[49].  The physiologic role of 
malectin is still not clear, but initial studies suggest that malectin plays a role in 
glycoprotein ERQC.  In studies using the misfolded glycoprotein alpha-1 
antitrypsin null Hong Kong (NHK) variant as a model substrate, malectin 
overexpression increased ER retention and decreased secretion of NHK.  The 
secreted NHK displayed immature ER-type N-glycans, suggesting malectin 
overexpression may impair further glycan processing, disturbing ERQC[50].  It 
was also suggested that malectin may be involved in ER associated degradation 
(ERAD), as malectin overexpression increased NHK association with OS-9, a 
component of the ERAD machinery for glycoproteins[51]. 
 After the terminal glucose residue is cleaved by GS1, the next glucose 
residue is cleaved from Glc2Man9GlcNAc2 by glucosidase II (GS2) to form 
Glc1Man9GlcNAc2 [52-54]  (GS2 also cleaves the innermost (alpha1,3)-linked 
glucose, the significance of which will be described further in the next section). 
GS2 is composed of two subunits: GS2α, the catalytically active subunit, and 
GS2β, the subunit containing an HDEL ER retention signal, responsible for ER 
localization of the heterodimer[55].  The physiologic importance of GS2 and 
formation of Glc1Man9GlcNAc2 N-glycan forms is highlighted by mutations in the 
GS2β subunit causing polycystic liver disease[56, 57].   
   Both glucosidases GS1 and GS2 can be inhibited in cells with either 1-
deoxynojirimycin (DNJ; glucose analog) or castanospermine (CAS; indolizine 
alkaloid).  Initial studies showed that pharmacological inhibition of ER 
glucosidases impairs trafficking of different glycoproteins to different degrees, but 
in general inhibits glycoprotein export with increased ER retention and increased 
ERAD[58, 59].  Interestingly, additional studies have shown that interfering with 
glucosidase activity can result in faster kinetics of glycoprotein folding yet with 
lesser efficiency (i.e. lower amounts of native forms produced), again, with more 
substrate glycoprotein degradation[60, 61].  Glucosidase inhibition can also 
activate the UPR[62].  As described below, these phenotypes are likely due to 
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absence of formation of Glc1Man9GlcNAc2 N-glycan forms that serve a critical 
role in glycoprotein ERQC[48].   
 
1.3.3  Processing Glc1Man9GlcNAc2 to Man9GlcNAc2 – the calnexin cycle 
  
Early studies demonstrated that monoglucosylated glycans accumulate 
when proteins are retained in the ER[50].  Glycoproteins with Glc1Man9GlcNAc2 
N-glycans are high-affinity substrates for the ER lectin-like chaperones calnexin 
(CNX) and calreticulin (CRT).  Glycoprotein association with CNX or CRT marks 
the beginning of what has been termed the ‘calnexin cycle’[63].  In the calnexin 
cycle, CNX and CRT are thought to play equivalent roles, as they have very 
similar structures and mechanisms of action, although CNX is a type 1 integral 
ER membrane protein while CRT resides in the ER lumen[48].  The calnexin 
cycle is based on repeated association and disassociation of incompletely-folded 
glycoproteins with pro-folding chaperones CNX and CRT (Figure 1.2).  The N-
glycans attached to substrate glycoproteins cycle between monoglucosylated 
(Glc1Man9GlcNAc2) and unglucosylated forms (Man9GlcNAc2) when bound or 
unbound to CNX/CRT, respectively.  GS2 plays two critical functions in the cycle: 
1) initial formation of Glc1Man9GlcNAc2 N-glycans from Glc2Man9GlcNAc2 
precursors, and 2) removal of the terminal glucose residue from 
Glc1Man9GlcNAc2 forms.  Deglucosylation to the Man9GlcNAc2 form mediates 
glycoprotein release from CNX/CRT, as CNX and CRT have very low affinity for 
unglucosylated glycans.  To complete the cycle, protein-bound Man9GlcNAc2 N-
glycans are reglucosylated to the Glc1Man9GlcNAc2 form by uridine diphosphate 
(UDP)-glucose:glycoprotein glucosyltransferase (UGGT1), which allows these 
glycoproteins to reassociate with CNX/CRT.  As described further, below, 
UGGT1 can also reglucosylate Man8GlcNAc2 and Man7GlcNAc2 N-glycans 
formed through demannosylation in the ER, although at a lower efficiency.   
UGGT1 plays a unique and critical role in the calnexin cycle because it is 
the only component that can recognize the folding status of glycoprotein 
" 10"
substrates.  Indeed, UGGT1 selectively reglucosylates only incompletely folded 
substrates (Figure 1.2); correctly folded substrates are not reglucosylated by 
UGGT1, rather, they proceed along the ER-to-Golgi anterograde trafficking 
pathway.  This function of UGGT1 to monitor folding of glycoprotein substrates 
and discriminate between correctly and incompletely folded forms matches the 
definition of glycoprotein ERQC, but the mechanism by which UGGT1 recognizes 
its substrates, and the downstream consequences of reglucosyation for specific 
substrates remain areas of active investigation.   
 
1.3.4  Calnexin cycle components – CRT, CNX, ERp57, UGGT1 
 
Calreticulin was first identified as a calcium-binding protein in skeletal 
muscle and named high-affinity calcium binding protein[64].  After being assigned 
many different names (e.g., calregulin, CRP55, CaBP3), a consensus for the 
term calreticulin (CRT) was finally achieved[65].  CRT was appreciated as having 
chaperone properties when it was demonstrated that it (and other ER chaperone 
proteins: BiP, GRP94, PDI) could be affinity purified by chromatography on a 
column of denatured (glyco)protein[66].   
Calnexin (CNX) was discovered as a calcium-binding, integral membrane 
phosphoprotein with high sequence identity to CRT[67].  An ERQC function for 
CNX was hypothesized based on data that unassembled T-cell receptor (TCR) 
subunits and major histocompatibility complex class I proteins (MHC I) exhibited 
prolonged interaction with CNX while being retained in the ER[68, 69].  
Additionally, CNX in HepG2 cells was found to associate with six major secretory 
glycoproteins including alpha-1 antitrypsin, and it was shown (by interfering with 
protein folding using the proline analog azetidine-2-carboxylic acid) that binding 
of glycoproteins to CNX was enhanced when they were misfolded[70]. 
ERp57 is a thiol oxidoreductase (with sequence similarity to protein 
disulfide isomerase) that binds to the P-domain of CNX and CRT[71].  Many 
(glyco)proteins require disulfide bond formation for correct folding, and ERp57 
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forms mixed disulfide bonds with glycoprotein folding intermediates[72].  ERp57 
has also been shown to accelerate the folding of ribonuclease B[73].  Importantly 
the ERp57-mediated folding required a monoglucosylated glycan and CNX[73]. 
UGGT1 was first appreciated in Trypanosoma cruzi because this organism 
initially transfers non-glucosylated Man9GlcNAc2 oligosaccharides to ER 
proteins[74], yet glucosylated Glc1Man9GlcNAc2, Glc1Man8GlcNAc2, and 
Glc1Man7GlcNAc2 oligosaccharides could be detected[75].  Monoglucosylation 
was found to require transport of a UDP-glucose donor into the ER lumen[76].  
Using an in vitro assay (composed of rat liver microsomes, UDP-[14C]Glc as a 
glucose donor, and purified thyroglobulin) it was shown that formation of 
radiolabeled Glc1Man7-9GlcNAc2 oligosaccharides occurred preferentially on 
denatured rather than native glycoprotein substrate[77], indicating that 
reglucosylation reflects the action of a ‘folding sensor’ in the cell.  Folding sensor 
behavior was directly demonstrated by showing that reglucosylation activity is 
dependent on protein-based characteristics and not just accessibility of the 
oligosaccharides.  Indeed, in vitro protease digestion of substrates abrogated 
reglucosylation activity even as the oligosaccharides were still recognized by 
lectin probes like concanavalin A[78].  By studying Schizosaccharomyces pombe 
bioengineered so that the UGGT1 enzyme was absent and only Man9GlcNAc2 N-
glycans were transferred to glycoproteins—the formation of the 
Glc1Man9GlcNAc2 glycan structure was found to be essential for cell viability 
under stress conditions[79], consistent with the idea that UGGT1 enzyme activity 
linked to the folding sensor may enhance glycoprotein folding quality and limit 
cytotoxicity.   
Studies of purified UGGT1 have indicated that the molecular mechanism 
by which UGGT1 recognizes its glycoprotein substrates is bipartite[80, 81].  At 
minimum, the substrate must have the innermost N-acetylglucosamine residue of 
the N-glycan, and must also have exposed hydrophobic residues[80].  Using 
artificially constructed RNAse heterodimers with mixed folded and unfolded 
halves, UGGT1 was found to reglucosylate N-glycans only on the misfolded 
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half[82], suggesting that for UGGT1-mediated reglucosylation, the N-glycan must 
be near the misfolded region of the substrate.  Interestingly, for a different 
glycoprotein substrate UGGT1 was reported to reglucosylate N-glycans more 
distant (40 angstroms) from local hydrophobic regions[83].  Despite these 
substrate-specific differences, it appears from all studies that UGGT1 can survey 
glycoprotein substrates for misfolded regions and reglucosylate attached N-
glycans when appropriate (Figure 1.2). 
Based on the availability of chemical glucosidase inhibitors (e.g., DNJ), it 
was shown that when GS2 was inhibited, the effect of UGGT1-mediated 
reglucosylation was to promote glycoprotein reassociation with, and impaired 
release from, CRT/CNX — and this resulted in delayed glycoprotein export from 
the ER[84].  This finding indicated that CRT/CNX binding is normally dynamic, 
with monoglucosylation enhancing the CRT/CNX-associated state and GS2 
activity enhancing the CRT/CNX-dissociated state — with each state having 
downstream consequences for substrate glycoproteins.  Overall, the implication 
of the above findings for mammalian cells is that the absence or insufficiency of 
any of the three key N-glycan-modifying enzymes (GS1, GS2 and UGGT1), or 
other components of the CRT/CNX cycle (Figure 1.2), can perturb the cycle and 
thereby result in deleterious consequences for glycoprotein quality control.   
 
1.3.5  Role of N-glycans and demannosylation in ER export and ERAD 
 
Trimming of mannose residues from N-linked glycans is linked to 
productive transport of one subset of glycoproteins through the Golgi complex, 
and is also linked to the processing of another subset of glycoproteins entrapped 
in the ER – most typically misfolded glycoproteins targeted for ERAD[85].   
For the subset of glycoproteins undergoing anterograde transport, 
demannosylation of N-glycans is a prerequisite for the formation of complex 
Golgi-modified glycans found on mature glycoproteins, which typically only have 
three or five core mannoses remaining from the original nine[86].  For this subset 
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of glycoproteins, trimming five mannoses from Man8GlcNAc2 to Man3GlcNAc2 
forms occurs through the action of Golgi-localized mannosidases {Golgi ManI 
(A,B,C), Golgi ManII, and Golgi ManIII[86]}.  These Golgi mannosidases are also 
able to remove the same mannoses from Glc1-3Man8-9GlcNAc2 N-glycans, 
allowing further processing of aberrant N-glycans arriving at the Golgi due to 
abnormal or failed ER quality control[86, 87] — often, such misfolded 
glycoproteins are recognized by quality control systems that operate in the Golgi 
complex, resulting in delivery to lysosomes for degradation[88].  Class I 
mannosidases specifically hydrolyze only (alpha1,2)-mannose linkages and are 
found in the ER and Golgi, while class II mannosidases will hydrolyze (alpha1,2), 
(alpha1,3), and (alpha1,6)-mannose linkages and are found in the Golgi and 
lysosomal compartments[89]. 
For forward transport of secretory proteins out of the ER and into the 
Golgi, two non-mutually exclusive mechanisms have been proposed: 1) bulk-
flow, and 2) receptor-mediated transport[90].  N-linked glycans are thought to 
play an important role in the second mechanism.  For example, ERGIC-53 is one 
protein (along with ERGL and VIP36) that is thought to act as a cargo receptor, 
and transfer correctly folded substrates to COP-II vesicles for transport out of the 
ER, into the Golgi[85, 91-93].  Similar to UGGT1, ERGIC-53 may have a bipartite 
recognition signal, and be able to sense folding status of its substrates[92].  As 
an example, ERGIC-53 recognizes both the high-mannose type N-glycan and a 
beta-hairpin loop structure present only in correctly folded cathepsin Z, an 
ERGIC-53 binding substrate[92].  Further, a pathologic role for ERGIC-53 
deficiency has been identified as a cause of a combined secretion defect for two 
serum glycoproteins and clotting factors, factor V (FV) and factor VIII (FVIII)[94].   
For substrates entrapped in the ER, such as under conditions in which 
ER-to-Golgi transport is blocked pharmacologically (e.g., using carbonyl cyanide 
m-chlorophenylhydrazone, a calcium ionophore), glycoproteins accumulate with 
a specific attached high-mannose N-glycan form, Man8GlcNAc2, lacking the B-
chain mannose (M8B)[95].  This Man8GlcNAc2 N-glycan form was also observed 
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using a temperature-sensitive model protein (ts045 VSV G protein) that is 
retained in the ER[96] — indicative of ER mannosidase I (ERmanI) activity with 
high specificity for the terminal B-chain mannose, allowing reglucosylation to 
continue to occur on the A-chain[71].   ERmanI is implicated in ERAD of 
glycoproteins (Figure 1.3), as inhibition of ERmanI stabilizes glycoproteins that 
are normally degraded[97, 98].  The mechanism of degradation involves 
recognition of the misfolded M8B-glycoprotein by the alpha-mannosidase I-like 
protein EDEMI[99-101].  EDEMI possesses little or no mannosidase activity, and 
seems to act as a ‘holdase’ that mediates transfer to other ERAD components, 
such as OS-9[99, 102].  There are two other EDEM homologs, EDEM2 and 
EDEM3.  EDEM3 has some mannosidase activity, and the C-branch mannose of 
the M8B N-glycan is cleaved by EDEM3 (or possibly Golgi mannosidase I) 
allowing OS-9 to specifically recognize this N-glycan lacking the C-branch 
mannose[103], with subsequent retrotranslocation to the cytoplasm for 
ubiquitination and ERAD via proteasomal proteolysis[99].  
Recent research is beginning to reveal the individual components of the 
mammalian ERAD/retrotranslocation complex, which has been termed the 
HRD1/SEL1L ERAD complex[99]. HRD1 is a transmembrane ubiquitin ligase 
which, together with SEL1L (that binds OS-9), forms a ubiquitin ligase 
complex[99].  OS-9 contains a mannose-receptor homology (MRH) domain, and 
it was shown that rather than binding to substrate N-glycans, OS-9 binds to N-
linked glycans of SEL1L with this domain, suggesting a mechanism for OS-9 
interaction with SEL1L, but complicating the true function of the OS-9 MRH 
domain[102].  Interestingly, ER-to-Golgi trafficking may also be necessary for 
ERAD of soluble glycoproteins[104].  Perhaps this transient exposure to the Golgi 
compartment allows for cleavage of the C-chain mannose, and subsequent 
targeting to the HRD1/SEL1L ERAD complex, possibly through direct interaction 
with OS-9[103]. 
One key question regarding ERQC is how the QC system distinguishes 
between terminally-misfolded glycoprotein forms and intermediate folding forms 
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that might have similar characteristics, targeting the former for degradation and 
the latter for reglucosylation and more refolding attempts[105].  In particular, if 
misfolded glycoprotein forms are in the calnexin cycle, but their foldedness does 
not improve during cycling, they could become trapped in the calnexin cycle.  
Based on data from cell-free assays, there is decreased efficiency of UGGT1-
mediated reglucosylation of lower mannose N-glycan forms (Man8GlcNAc2, 
Man7GlcNAc2)[78].  Consequently, it was thought that N-glycan 
demannosylation—either of the B- and C- chains to decrease affinity of UGGT1, 
or of the A-chain to completely prevent UGGT1-mediated reglucosylation—might 
favor release of misfolded glycoproteins from the CNX cycle, leading to 
degradative fates[105].     
In contrast to the finding above, it was recently shown in S. pombe that 
UGGT1-mediated reglucosylation efficiency does not decrease on mannose 
removal, while it is GS2 whose efficiency of deglucosylation decreases 
precipitously as mannose residues are removed from Man9GlcNAc2 N-
glycans[106].  The MRH domain of OS-9 does interact specifically with N-glycans 
lacking terminal C- chain mannoses, including monoglucosylated forms 
(Glc1M8C, Glc1M7B,C)[103, 107].  This opens the possibility of an alternative 
means of glycoprotein disposal to that proposed in the previous paragraph, 
where in this instance removal of the terminal C- chain mannose by EDEM3 and 
subsequent recognition by OS-9 may lead to ERAD of monoglucosylated forms 
directly from the calnexin cycle[103, 106].  Interestingly, ERAD of the misfolded 
alpha-1 antitrypsin variant null Hong Kong (NHK) is accelerated when the 
glucosidase inhibitor CAS is added during chase after metabolic labeling, 
implying deglucosylation may not be necessary to target misfolded glycoproteins 
to ERAD[108]. 
Initial studies strongly implicated Man8GlcNAc2 N-glycan forms as 
sufficient for targeting to ERAD, but more recently it has been proposed that 
Man5-7GlcNAc2 N-glycans may serve as even stronger signals for ERAD (Figure 
1.3).  Using [3H]-mannose pulse-labeling, Lederkremer’s group showed that 
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asialoglycoprotein receptor H2a N-glycans accumulated in Man5GlcNAc2 and 
Man6GlcNAc2 forms when proteasomal proteolysis was inhibited with MG-132.  
When the mannosidase inhibitor deoxymannojirimycin (DMJ) was added during 
the chase, the N-glycan forms shifted to those with more mannose residues, 
namely Man6-9GlcNAc2, and degradation of H2a was inhibited.  These effects 
were not seen with swainsinone, an inhibitor of class II mannosidases (such as 
ER and Golgi mannosidase II); thus, the authors postulated that endogenous 
ERmanI activity involves cleavage beyond the Man8GlcNAc2 form, all the way to 
Man5GlcNAc2, and that these further mannose cleavage events are required for 
efficient ERAD[109].   
Based on in vitro studies[110, 111], it was not thought that ERmanI at 
physiological concentrations could cleave beyond the terminal B-chain 
mannose[48, 112, 113], but it was shown that ERmanI could cleave to the 
Man5GlcNAc2 form at high concentrations[114].  Indeed, it has been proposed 
that ERmanI is concentrated in a pericentriolar compartment called the ER 
quality control (ERQC) compartment, where it may reach a high enough 
concentration in vivo to cleave additional mannoses beyond the Man8GlcNAc2 
form[109].  Characterization of the ERQC is in the early stages, but results do 
indicate its involvement in degradation of misfolded ER proteins by both ERAD 
and autophagy.  First, when proteasomal proteolysis is inhibited by lactacystin 
treatment, the ERAD substrate H2a accumulates in the ERQC[109].  Second, 
when lysosomal degradation—and therefore autophagy—is inhibited by 
treatment with leupeptin, the lysosomal marker Lamp1 accumulates in the 
ERQC[109].    
Intriguingly, with lactacystin treatment, CNX and CRT become 
concentrated in the ERQC compartment, while UGGT1 does not[115].  The 
significance of this finding is also unclear, but may indicate that once 
glycoproteins enter the ERQC compartment, UGGT1-mediated reglucosylation 
no longer has a major role in their eventual fate.     
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1.3.6  Insoluble protein aggregates accumulate in cytoplasmic compartments  
 
If ER glycoproteins are not delivered to the Golgi or degraded through 
ERAD, they become especially susceptible to aggregation.  These aggregates 
are often insoluble in nonionic detergent lysis buffers, such as 1% Triton X-
100[116, 117].  Detergent insolubility has been observed for multiple mutant 
glycoproteins, and indeed such protein aggregation is thought to play a role in the 
pathogenesis of numerous diseases[118-122] such as neurodegenerative 
diseases and the liver disease associated with alpha-1 antitrypsin 
deficiency[117].  Thus, the mechanism(s) by which cells compartmentalize, 
degrade, and may potentially resolubilize insoluble aggregates is a critical area of 
medical research.  Recent findings indicate that cells manage cytoplasmic and 
ER aggregates in distinct ways, but there is also evidence that these two 
pathways may intermingle[117].   
 In the cytoplasm, a new paradigm for managing misfolded proteins and 
protein aggregates has recently emerged.  Briefly, misfolded proteins are 
ubiquitinated and targeted to the juxtanuclear QC compartment (JUNQ), a 
dynamic compartment that rapidly exchanges its contents with the cytosol.  
Alternatively, misfolded proteins can also be transported to insoluble protein 
deposits (IPODs), which tend to store insoluble protein aggregates at the cell 
periphery [117], and may be a site for misfolded proteins that overflow when their 
accumulation exceeds capacity of the JUNQ compartment.  Proteins localized to 
JUNQ or IPODs are sensitive or resistant to trypsin digestion, respectively — 
supporting the idea that IPODs are sites where aggregated proteins are 
delivered[123].  The main route of degradation from the JUNQ compartment is 
through the ubiquitin-proteasome system (UPS), whereas insoluble aggregates in 
IPODs are thought to be degraded by autophagy (Atg8, the yeast homolog of the 
mammalian autophagy marker LC3, localizes to IPODs)[117].  The JUNQ 
compartment shares many characteristics with another cytoplasmic structure 
called the ‘aggresome’, which also exhibits juxtanuclear localization, ubiquitinated 
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proteins, proteasomes, and microtubular transport of incoming proteins[116, 117, 
123, 124].  It seems that JUNQ and aggresomes may be different structures, as 
aggresomes colocalize with spindle pole bodies, while JUNQ does not[117].  
The ER quality control (ERQC) system may help transport soluble or 
insoluble ER glycoproteins to similar or related cytoplasmic compartments, and 
the mechanism may be different for luminal and transmembrane ER 
glycoproteins (Figure 1.4).  For example, cystic fibrosis transmembrane 
conductance regulator (CFTR, which has difficulty in anterograde transport from 
the ER) can accumulate in aggresomes[124], presumably after dislocation from 
the ER membrane, but there are no reports of lumenal ER proteins accumulating 
in aggresomes.  Rather, insoluble aggregates of the ER luminal glycoprotein 
fibronectin may be transported out of the ER through a vesicular system, for 
eventual lysosomal degradation.  These ER-derived vesicles are distinct from 
COPII coated vesicles used for ER-to-Golgi transport[125, 126].  They also 
contain high amounts of EDEM1 and may be related to vesicles termed 
‘EDEMosomes’, involved in degradation of ERAD components (ERAD 
tuning)[127].  Many questions remain regarding the ERQC of misfolded soluble 
and insoluble glycoproteins, but it is generally thought that soluble and insoluble 
glycoproteins are processed differently (Figure 1.4).  For example, mutant alpha-
1 antitrypsin Z allele (ATZ) is thought accumulate in the ER in both soluble and 
insoluble forms that are degraded by either the UPS or autophagy, 
respectively[128].  Insoluble forms of ER entrapped proteins are often described 
to accumulate in the ER-associated compartment (ERAC)[129, 130].  As an 
example, eGFP-tagged CFTR accumulates in both soluble and insoluble pools, 
and both localize to the ERAC.  Whereas the soluble pool is degraded through 
the UPS, the insoluble pool is degraded by autophagy[129].  ERACs also have a 
juxtanuclear localization; some substrates are delivered and localized exclusively 
to the ERAC and cannot be found in the rest of the ER[130]. ERACs are 
proposed to promote ER homeostasis by partitioning aggregated (presumably 
non-functional, possibly toxic) proteins away from the rest of the ER[129].  Similar 
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to cytoplasmic aggresomes, microtubules are necessary for trafficking of 
substrate proteins to the ERAC[131].  Experimentally, immunofluorescent 
staining for the translocon component Sec63 can be used to identify the ERAC 
compartment[130].  Presently, experimental results do not clearly define the 
ERAC and another hypothesized ‘ERQC compartment’ as distinct compartments, 
therefore these two compartments will be termed ERQC/ ERAC for the remainder 
of this review (Figure 1.4).   
Sequestrations of misfolded proteins in subregions of the ER (ERQC/ 
ERAC compartment) have also been called Russel bodies, a form of inclusion 
body[129, 131, 132] that may be either electron-dense or electron-lucent, 
depending upon the misfolded substrate contained within them[133].  Again, it is 
unclear whether these unique names reflect unique structures, or if there is 
overlap between them.  Classically, Russel bodies are filled with protein 
aggregates of misfolded immunoglobulin along with certain ER resident proteins 
such as CNX, whereas others (BiP, PDI, ERp72) are excluded, suggesting 
selective protein entry into, or exclusion from, this compartment[132].  As CNX is 
thought to interact with glycoprotein substrates, its inclusion in Russel bodies 
may signify an activity to limit, or even reverse, glycoprotein aggregation.  Thus, 
in future work, it will be important to examine and understand the effects of N-
linked glycoprotein processing on the aggregation of misfolded secretory 
glycoprotein substrates. 
 
1.4  Conclusion   
 
 N-linked glycosylation of proteins in the ER initiates entry into a complex 
glycoprotein-specific ERQC system that maintains the fidelity of the secretory 
and transmembrane proteome.  The effectiveness of the ERQC is quite sensitive 
to glycoproteins with even slight amino acid substitutions, targeting them for 
ERAD (despite that they may still have the potential to contribute a measure of 
bioactivity).  The CNX cycle figures prominently into glycoprotein ERQC, with 
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UGGT1, the reglucosylating enzyme serving as a primary folding sensor to 
mediate downstream consequences for non-native glycoprotein folding forms.  
How the glycoprotein ERQC system functions to degrade terminally misfolded 
glycoproteins, and what happens when these degradation pathways are 
overwhelmed are key questions for future exploration.  Although many of the 
components of glycoprotein ERQC have been identified, the recent discovery of 
new proteins (e.g., malectin) makes it likely that additional glycoprotein ERQC 
components remain to be identified.  Our understanding of the mechanistic 
details of glycoprotein ERQC will help to expose therapeutic targets for the ever-
increasing list of ER storage diseases[2]. 
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1.5  Figures 
 
Figure 1.1  Structure of N-linked glycans 
N-linked oligosaccharides are assembled on the ER membrane, and then 
transferred en bloc to Asn side chains of newly translocated proteins harboring 
consensus N-glycosylation sites (Asn-X(any amino acid except proline)-Ser/Thr.  
The 14-sugar form, starting from the Asn residue, contains two N-
acetylglucosamines (GlcNAc, squares), nine mannoses (circles), and three 
glucoses that are all on the A-chain branch of the triantennary mannose structure 
(triangles).  Glycosidic bond types are indicated, as are ER and Golgi localized 
glycosidases responsible for trimming the N-glycan to smaller forms. 
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Figure 1.2  N-glycan processing in the calnexin cycle 
Glycoproteins first enter the calnexin cycle when the penultimate glucose of the 
attached N-glycan is cleaved by glucosidase II (GS2).  The resulting 
monoglucosylated N-glycan can serve as a high-affinity substrate for the lectin-
like chaperones calnexin (CNX) and calreticulin (CRT) the associated 
oxidoreductase ERp57.  The ability of the substrate to re-associate with the 
lectin-like chaperones is terminated when GS2 acts to remove the terminal 
glucose residue from the N-glycan.  At this point, the glycoprotein substrate’s 
folding status is surveyed by the ‘folding sensor’ component of the calnexin cycle, 
UDP-glucose:glycoprotein glucosyltransferase (UGGT1).  UGGT1 reglucosylates 
nearly-native folding forms of glycoprotein substrates, converting them again into 
high-affinity substrate for CNX/CRT, and therefore allowing for another round 
(and potentially, multiple rounds) of CNX/CRT association.  Substrates are 
eventually released from the calnexin cycle upon demannosylation of N-glycans.  
The mechanism for permanent exit from the cycle involves either termination of 
UGGT1 reglucosylation activity of demannosylated N-glycans, or active 
recognition of demannosylated forms by ER exit machinery or ERAD 
components.   
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Figure 1.3  Glycoprotein ERAD 
Degradation of terminally misfolded glycoproteins through ERAD is likely initiated 
by cleavage of the terminal B-chain mannose of Man9GlcNAc2 (and possibly 
Glc1Man9GlcNAc2) N-glycan forms by ER mannosidase I (ERmanI). This results 
in formation and recognition of this specific Man8GlcNAc2 (M8B) form by ER 
degradation enhancing alpha-mannosidase-like 1 (EDEM1).  Then, removal of 
the terminal C-chain mannose — either: 1) directly by EDEM3 or possibly Golgi 
mannosidase I, or 2) by highly concentrated ERman1 in the ERQC compartment 
— exposes an alpha1-6 linked mannose that is recognized by OS-9.  OS-9 
facilitates transport of the misfolded substrate to the core ERAD HRD1/SEL1L 
complex, and subsequent retrotranslocation to the cytoplasm for degradation by 
the 26S proteasome.       
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Figure 1.4  ERQC of insoluble glycoproteins 
Some misfolded glycoproteins are known to form insoluble aggregates or ordered 
polymers in the ER, and UGGT1-mediated modification of glucosylation status 
(monoglucosylated or unglucosylated) may play a role to limit insolubility.  The 
soluble-to-insoluble transition may be related to compartmentalization in the 
ERQC/ERAC compartment, and insoluble substrates may also be resolubilized.  
Soluble forms of both luminal and transmembrane glycoproteins tend to be 
degraded through ERAD, while insoluble forms tend to be degraded via 
autophagy, although the mechanism by which insoluble ER proteins get to the 
lysosome is not entirely clear.  Luminal insoluble glycoproteins may be packaged 
into EDEM1-containing vesicles (EDEMosomes) and transported to the 
lysosome.  Transmembrane insoluble glycoproteins could accumulate in the 
aggresome and then be degraded by the proteasome, or targeted by an unknown 
mechanism to the lysosome for degradation.   
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Chapter 2 
UDP-glucose:glycoprotein glucosyltransferase (UGGT1) promotes 
substrate solubility in the endoplasmic reticulum 
 
2.1  Introduction 
  
Although the amino acid sequence of a protein has all the information 
required to fold into its native functional conformation[1], folding pathways and 
efficiency are dramatically influenced by the environment[2].  Newly-made 
secretory and transmembrane proteins in the endoplasmic reticulum (ER) require 
the assistance of chaperones and enzymes to fold to their native conformation[2].  
Recognition, retention, refolding, and degradation of misfolded protein substrates 
in the ER are referred to, collectively, as ER quality control[2-6].  Protein folding 
failure in the ER can lead to insolubility, either by formation of protein aggregates, 
or by ordered polymerization.  Once rendered insoluble in the ER, entrapped 
proteins are either degraded (through autophagy), or can persist as undegraded 
insoluble complexes possibly contributing to cell toxicity, or may be re-
solubilized[7-9].  The mechanisms that promote protein solubility in the ER are 
poorly understood.    
The folding, trafficking and degradation of glycoproteins is coupled with 
the modification of N-linked oligosaccharides[10, 11].  Upon translocation into the 
ER, a preassembled oligosaccharide core (Glc3Man9GlcNAc2) is transferred to 
asparagine residues within the acceptor sequence Asn-Xxx-Ser/Thr.  
Glucosidases I and II sequentially trim this core to a monoglucosylated glycan 
that can mediate binding to lectin-like ER chaperones calreticulin (CRT) and 
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calnexin (CNX).  Interaction with CRT and CNX serves to retain improperly folded 
substrates in the ER as a key step in glycoprotein quality control, as well as to 
promote folding through interactions with ERp57[12]. Upon release from 
CRT/CNX, glucosidase II can remove the remaining glucose to produce a 
product that if folded properly traffics to the Golgi, or if folded improperly is 
directed to ER-associated degradation (ERAD) or is subject to reglucosylation for 
interaction with CRT/CNX. Uridine diphosphate (UDP)-glucose:glycoprotein 
glucosyltransferase (UGGT1) is proposed to be a central gatekeeper for ER 
quality control for glycoproteins, as it recognizes the partially folded status as a 
substrate to reglucosylate the deglucosylated N-glycan to direct another round of 
interaction with CRT/CNX[10, 13].  
There are two UGGT genes in the mouse, Uggt1 and Uggt2[14].  The 
product of Uggt1 has reglucosylation activity in vitro and its deletion destroys 
reglucosylation activity in cells and is embryonic lethal at day E13 in mice[15].  In 
contrast, the product of Uggt2 has not been demonstrated to have 
reglucosylation activity and its function remains unknown.  Interestingly, 
exchange of the UGGT1 80% amino terminal substrate recognition domain into 
UGGT2 partially restores reglucosylation activity in vitro, demonstrating that the 
carboxy terminal 20% of UGGT2 can function as a glucosyltransferase in the 
proper context[16].    
While the purported mechanism for UGGT1-mediated quality control—
reiterative monoglucosylation of deglucosylated N-glycans on incompletely folded 
glycoproteins, and subsequent rounds of association of these glycoproteins with 
CRT/CNX—has been extensively described[17-21], it remains unclear the extent 
to which UGGT1 influences the susceptibility of ER substrate proteins to form 
insoluble protein aggregates or polymers.  In this study, we used two different 
alpha-1 antitrypsin (AAT) variants prone to misfolding, to investigate the impact 
of UGGT1 on the solubility of these glycoprotein substrates.  One variant is the 
well-studied ERAD substrate known as null Hong Kong variant (NHK); the other 
is the more common mutant Z allele (ATZ).  Both alleles cause AAT deficiency 
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(the most common genetic liver disease in children), which is a representative of 
the class of ‘conformational diseases’ caused by retention of misfolded 
glycoproteins in the ER[22-25].  In this report, using Uggt1-/- mouse embryonic 
fibroblasts (MEFs) expressing NHK or ATZ, and complemented with plasmid-
encoded UGGT1, we demonstrate that UGGT1 enzymatic activity—in 
conjunction with lectin-like chaperones—helps to limit aggregation and polymer 
formation of misfolded glycoprotein substrates, decreasing their BiP association, 
and decreasing ER stress. 
 
2.2  Results 
  
UGGT1 increases solubility of alpha-1 antitrypsin (AAT) mutants: NHK and ATZ.  
Uggt1-/- MEFs have undetectable levels of UGGT1 protein and enzymatic 
monoglucosylation activity[15].  UGGT1 in the ER is associated with misfolded 
NHK and ATZ variants of AAT[26, 27].  ATZ is predisposed to form insoluble 
ordered polymers[28] whereas ER-entrapped NHK can be recovered in a 
detergent-soluble pool in UGGT1-expressing cells[29].   
 To directly investigate the effect of UGGT1 on NHK, ATZ, or wild-type AAT 
(wt-AAT) solubility, Uggt1-/- MEFs (or those complemented with plasmid-encoded 
UGGT1) expressing these substrates were metabolically labeled with [35S]-
methionine/cysteine to approach steady state.  By quantitative 
immunoprecipitation (Figure 2.S1A), we determined that over the course of the 
metabolic labeling period (24 h), a fraction of mutant NHK molecules was 
secreted; a second portion was recovered in the intracellular detergent-soluble 
supernatant fraction; and a third was recovered as aggregates that failed to be 
solubilized from Uggt1-/- MEFs lysed in nonionic detergents (Figure 2.1A).  This 
‘detergent-insoluble fraction’ was indeed solubilized in SDS-containing detergent 
extracts.   
 Whereas endoglycosidase H(EndoH)-resistant NHK molecules were found 
in the secreted fraction, both the soluble and detergent-insoluble intracellular 
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fractions were EndoH-sensitive, indicating that neither the soluble nor insoluble 
intracellular pool had arrived in a Golgi compartment from which they could be 
further modified by Golgi N-glycan processing enzymes (Figure 2.2D).  We 
confirmed that a fraction of mutant NHK molecules forms detergent-insoluble 
protein aggregates by several independent approaches.  First, pulse-chase 
experiments demonstrated that newly-synthesized NHK was not initially 
recovered in the detergent-insoluble fraction but became so as a function of 
chase, indicating time-dependent specificity (Figure 2.2C).  Second, we 
compared solubility of NHK using three standard detergent lysis methods [(1) 
CHAPS (2%w/v); (2) Nonidet P-40 (1%v/v); (3) Triton X-100 (0.5%w/v) and 
sodium deoxycholate (0.5%w/v)] that have been used for analysis of AAT and its 
variants[27, 30, 31]]: in each case, a detergent-insoluble fraction of NHK was 
recovered (Figure 2.S1B).  Finally, intracellular wt-AAT was always undetectable 
in the insoluble fraction (Figure 2.1C, 2.2A), indicating that recovery in the 
detergent-insoluble pool was not caused by failure to disrupt cellular membranes 
from Uggt1-/- MEFs.  These findings plus recent reports[32] provide strong 
evidence that NHK is predisposed to aberrant protein aggregation.   
Complementation of Uggt1-/- MEFs with UGGT1 greatly expanded the 
steady-state intracellular pool of NHK molecules (Figure 2.1A).  Whereas only 
half as many NHK molecules were secreted, there was a great expansion of the 
pool of soluble intracellular NHK molecules (red bar, Figure 2.1A, middle), and a 
decrease in the pool of detergent-insoluble NHK (blue bar, Figure 2.1A, middle).  
Additionally, the total soluble (extracellular+soluble)/insoluble NHK ratio 
increased with UGGT1 cotransfection (Figure 2.1A, right).  Thus, the net effect of 
coexpressing UGGT1 was to increase the solubility of NHK.   
The same experimental analysis was used to investigate ATZ trafficking in 
the ER.  Whereas NHK cannot undergo loop-sheet polymerization, recovery of 
detergent insoluble ATZ is thought to reflect the formation of ordered 
polymers[28].  Here as well, UGGT1 expression increased the total 
soluble/insoluble ratio of ATZ almost 2-fold, (with little effect on the secreted 
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fraction, Figure 2.1B).  Also, similarly to NHK, in pulse-chase experiments, ATZ 
was not detected in the detergent-insoluble fraction initially, but accumulated in 
the insoluble fraction over time (Figure 2.2B).  Furthermore, to directly detect ATZ 
polymers in transfected cells, we utilized a recently developed monoclonal 
antibody (2C1) that specifically recognizes ATZ polymers[33].  
Immunofluorescent co-staining with 2C1 and polyclonal anti-AAT antibody—and 
subsequent quantitation of signal intensity in the entire cell volume through Z-
stack analysis—revealed a decrease in the ratio of 2C1 to AAT signal in cells 
cotransfected with UGGT1 (Figures 2.S2A-B).   
Thus, for mutant glycoproteins that are prone to misfolding in two distinctly 
different ways [formation of ordered polymers (ATZ) or formation of disordered 
aggregates (NHK)], UGGT1 increased substrate solubility.  By contrast, UGGT1 
had no significant effect on the behavior of wt-AAT, consistent with the 
observation that wt-AAT molecules were soluble in Uggt1-/- MEFs even before 
complementation with UGGT1 (Figure 2.1C).   
 
UGGT1 promotes NHK solubility through monoglucosylation activity.  To 
investigate whether increased NHK solubility was due to UGGT1 chaperone 
function or enzymatic reglucosylation activity[20], we eliminated the enzymatic 
contribution of UGGT1 either by glucosidase inhibition (with castanospermine 
(CAS), which prevents formation of unglucosylated N-glycans that serve as 
substrates for UGGT1-mediated monoglucosylation) or by complementation with 
UGGT1 variants lacking monoglucosylation activity.  When CAS was included 
throughout the labeling period, UGGT1 did not increase solubility of NHK (Figure 
2.3A).  Furthermore, a catalytically-inactive UGGT1 (lacking six amino acids 
within the catalytic site, called ΔUGGT1[14]) was similarly unable to augment the 
solubility of NHK (Figure 2.3A).  However, a UGGT1/UGGT2 chimera (in which 
the C-terminal 20% of UGGT2 replaced the C-terminal 20% of UGGT1) bearing 
~half of the enzymatic activity of native UGGT1[16] increased NHK solubility, and 
this effect was similarly eliminated by CAS treatment (Figure 2.3A).  In parallel to 
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these NHK results, we found that enhanced solubility of ATZ also correlated with 
the presence of enzymatic UGGT1 monoglucosylation activity (Figure 2.S3A).   
Since lectin-like chaperones CRT and CNX recognize monoglucosylated 
N-glycans, as an indirect measure of monoglucosylation we examined NHK 
association with CNX at the end of the 24 h metabolic labeling of Uggt1-/- MEFs ± 
UGGT1 complementation.  As in previous experiments, 2% CHAPS was included 
in the cell lysis buffer to maintain CNX–substrate interactions[34].  However, only 
when Uggt1-/- MEFs were complemented with enzymatically active 
glucosyltransferase was the CNX-NHK association detected (Figure 2.3B).   
To directly establish that increased NHK solubility in UGGT1-expressing 
cells is caused by enzymatic monoglucosylation activity, we used jack-bean 
alpha mannosidase [JBM, an exo-mannosidase that cleaves eight mannose 
residues from unglucosylated ER-type N-glycans, but only five mannose residues 
from monoglucosylated ER-type N-glycans (Figure 2.3C)] to create diagnostic 
digests to assess the glycosylation status of steady-state soluble and detergent-
insoluble pools.  Upon JBM digestion, intracellular soluble NHK from UGGT1-
expressing MEFs produced a predominant higher molecular mass digestion 
product distinct from the primary form recovered in Uggt1-/- MEFs (Figure 2.3D, 
left panel).  By contrast, in spite of UGGT1 expression, intracellular detergent-
insoluble NHK, upon JBM digestion, produced a predominant lower molecular 
mass digestion product that co-migrated with that from UGGT1-deficient MEFs 
(Figure 2.3D, right panel).  Strikingly, upon UGGT1-complementation, the 
majority of detergent-insoluble NHK lacks monoglucosylated N-glycans whereas 
the majority of soluble NHK from the same cells bear monoglucosylated N-
glycans.  The findings strongly suggest that increased solubility of the substrate 
is a consequence of its N-glycan monoglucosylation. 
 
UGGT1 maintains solubility of NHK over time.  As noted above, all newly 
synthesized NHK, ATZ and wt-AAT molecules begin in the soluble fraction; thus 
the accumulation of NHK and ATZ molecules takes time.  While steady-state 
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labeling provides useful conditions for determining the sizes of soluble and 
insoluble intracellular pools, it does not provide insight into the entry or exit of 
molecules in these fractions.  Therefore, after steady-state labeling, we followed 
pools of NHK for up to 6 h in the absence of further metabolic labeling.  As 
previously observed (Figure 2.1A), intracellular NHK solubility was enhanced in 
UGGT1-expressing cells (Figure 2.4A-B).  At 3 h and 6 h after the steady-state 
labeling period, the pool of soluble NHK decreased in Uggt1-/- MEFs both without 
and with UGGT1 complementation.  However, without UGGT1 complementation, 
some of the molecules formerly in the soluble pool entered and expanded the 
detergent-insoluble pool (Figure 2.4A-B), whereas in the presence of UGGT1, 
expansion of the detergent-insoluble pool was prevented.  Indeed, despite a 
decrease in soluble NHK as a function of chase time, the relative increase in 
NHK solubility as a consequence of UGGT1 activity was maintained at all times 
(Figure 2.4C).  Thus, the results suggest that UGGT1 activity limits misfolded 
glycoprotein entry into detergent-insoluble complexes. 
 
ERAD inhibition further expands NHK solubility induced by UGGT1.  To 
investigate whether NHK is degraded by ER-associated degradation (ERAD) 
during the course of our experiments, NHK transfected cells were treated with 
kifunensine (KIF, a mannosidase inhibitor) for the entire 24 h metabolic labeling 
period.  KIF potently inhibits glycoprotein ERAD[35], including the degradation of 
NHK[36, 37].  By measuring the amount of steady-state NHK recovered in all 
fractions and normalizing this total to its synthesis in the same cells, the amount 
of NHK degraded under each experimental condition could be deduced (Figure 
2.5A-B).  When KIF was present, the amount of NHK recovered in the insoluble 
fraction increased, both with and without UGGT1 co-transfection (Figure 2.5A-B).  
However, in the presence of UGGT1, KIF treatment also promoted an increase in 
total soluble NHK (Figure 2.5A-C).  Likewise, using a pulse-chase technique, 
when UGGT1 was present, KIF treatment stabilized soluble NHK in cells (Figure 
2.5D).  Interestingly, this KIF-induced increase in soluble NHK was not seen in 
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Uggt1-/- MEFs cotransfected with empty vector (Figure 2.5B).  As ERAD inhibition 
expands NHK solubility caused by UGGT1 activity, the effect of UGGT1 to 
promote solubility of NHK in the absence of ERAD inhibition is likely to be larger 
than the magnitude shown in Figures 2.1-2.3.   
 
Relative contribution of N-glycan addition versus monoglucosylation on the 
solubility of misfolded mutant AAT.  NHK, ATZ and wt-AAT each have three N-
linked glycosylation sites at positions N46, N83, and N247.  To investigate the 
contribution of each of these N-glycans to NHK solubility, we eliminated N-
glycosylation at these sites by mutagenizing each Asn acceptor to Gln, and 
prepared all possible combinations of one-site or two-site N-glycosylation 
mutants.  We then measured the total soluble/insoluble ratio for each of the 
seven constructs, with or without UGGT1 complementation (Figure 2.6A-B).  The 
majority of unglycosylated NHK (NHK-N46Q_N83Q_N247Q or NHKQQQ) was 
insoluble, and UGGT1 cotransfection had no effect on the solubility of this 
construct (Figure 2.6B, bars 1-2).  For the NHK constructs with only one N-
glycosylation site (NHK-N83Q_N247Q, NHK-N46Q_N247Q, and NHK-
N46Q_N83Q), in the absence of UGGT1, solubility did not increase, but solubility 
was enhanced by expression of UGGT1 (Figure 2.6B, bars 3-8).  The largest 
UGGT1-mediated solubility increase occurred with the NHK-N46Q_N247Q 
mutant, perhaps indicating particular importance of the N83 N-glycan (Figure 
2.6B, bars 5-6).  For the NHK constructs with two N-glycosylation sites (NHK-
N247Q, NHK-N83Q, NHK-N46Q), solubility increased both with and without 
UGGT1, but the increase was greater when UGGT1 was present (Figure 2.6B, 
bars 9-14), and each of the double-glycan mutants behaved comparably. Similar 
to Figure 2.1A, the fully glycosylated protein was the most soluble NHK construct, 
but UGGT1 expression conferred additional solubility (Figure 2.6B, bars 15-16).  
The results indicate that each N-linked glycan contributes to the solubility of NHK, 
but maximal solubility is achieved only in UGGT1-expressing cells.   
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UGGT1 cotransfection reduces NHK association with BiP, and BiP-Luciferase 
response.  The binding of unfolded and misfolded proteins in the ER to BiP 
activates the Unfolded Protein Response (UPR)[38-40].  To examine BiP 
association with NHK, DSP-crosslinked cell lysates were analyzed by 
immunoprecipitation with anti-AAT, and the immunoprecipitates subjected to 
reducing SDS-PAGE and immunoblotting with anti-BiP and anti-AAT.  Consistent 
with the metabolic labeling results of Figure 2.1A, there was increased NHK in 
the soluble fraction of Uggt1-/- MEFs complemented with UGGT1 (Figure 2.7A, 
lower panel).  However, despite that there was more NHK present in the soluble 
pool, the actual amount of BiP associated with NHK in that pool decreased 
(Figure 2.7A, quantified in Figure 2.7B).  To investigate UPR activation in cells 
expressing NHK, ATZ, or wt-AAT, we co-expressed BiP-Luciferase and 
normalized the signal from the ER stress response reporter directly to the 
abundance of the misfolded protein substrate.  Interestingly, neither wt-AAT nor 
mutant ATZ expression (data not shown) increased BiP-Luciferase activity, 
regardless of the presence or absence of UGGT1 expression (Figure 2.7C, bars 
1-2), consistent with previous reports[41-43].  By contrast, NHK expression 
induced an appreciable BiP-Luciferase response that was attenuated in cells 
complemented with UGGT1 (Figure 2.7C, bars 3-4).  Notably, UGGT1 
complementation did not diminish (and actually augmented) UPR activation to 
tunicamycin treatment, presumably because of the increased protein load in the 
ER and the fact that reglucosylation activity is irrelevant in cells in which N-linked 
glycosylation has been blocked by tunicamycin (Figure 2.7C, bars 5-6).  Taken 
together, the results of Figure 7 indicate that BiP-association with a misfolded 
glycoprotein substrate decreases as a consequence of substrate 
monoglucosylation, which reduces UPR activation in these cells.   
 
The ER lectin calreticulin is linked to increased solubility of monoglucosylated 
glycoprotein substrate.  To explore whether UGGT1-mediated solubility of NHK is 
due to increased interaction with lectin-like chaperones, we performed CRT 
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siRNA-mediated knockdown in Uggt1-/- MEFs (CRT, the most abundant soluble 
ER lectin, is likely to interact with a high fraction of soluble glycoprotein 
substrates).  In both DSP crosslinked and non-crosslinked cell lysates, interaction 
between NHK and CRT was readily demonstrated (Figure 2.8A).  CRT siRNA 
knockdown (KD) was more than 50% efficient in Uggt1-/- MEFs at 48 h post-
siRNA treatment, and this itself did not upregulate other ER chaperones, as well 
as CNX (Figure 2.8B).  However, upon NHK transfection in these cells, CRT KD 
largely blocked the increase of NHK solubility caused by UGGT1 
complementation (Figure 2.8C-E).  Also, CRT KD increased the proportion of 
insoluble NHK, and blocked the effect of UGGT1 to decrease the proportion of 
insoluble NHK (Figure 2.8D).  The data indicate that abundance of CRT is a key 
factor in promoting solubility of monoglucosylated N-linked glycoprotein 
substrates in the ER.   
 
2.3  Discussion 
 
Protein solubility, or more importantly, the formation of insoluble protein 
aggregates or polymers, is thought to play a fundamental role in the pathology of 
a wide array of human diseases[44].  Mutations in secreted proteins can disrupt 
their normal ER folding program, resulting in aggregation and cell 
stress/death[45-47].  Regulation of aggregate/polymer formation and the role of 
chaperone interaction in this process are incompletely understood.  In this report 
we describe how UGGT1 enzymatic activity correlates with increased solubility of 
two model glycoproteins susceptible to aggregation and polymerization.   
 A large body of work has delineated the key role of UGGT1 in 
reglucosylation of nonnative glycoprotein folding intermediates, and subsequent 
reassociation with the lectin-like chaperones CRT and CNX[17-21, 48, 49].  Here, 
we show that the ATZ allele of AAT, which is prone to misfolding, formed more 
insoluble polymers in UGGT1-deficient cells (Figure 2.1B).  The null Hong Kong 
(NHK) variant of AAT also accumulated in the insoluble fraction, and the 
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proportion detected in the insoluble pool after 24 h labeling decreased in the 
presence of UGGT1 activity (Figure 2.1A).  Interestingly, UGGT1 maintained the 
solubility of both nonnative ER forms of these AAT variants, but the 
consequences of this increased solubility were different for NHK and ATZ.  For 
NHK, soluble nonnative forms were retained in the ER, and the secretion rate 
was lower upon UGGT1 complementation; thus, UGGT1 increases quality control 
for secretion of nonnative NHK.  For ATZ, UGGT1 retained soluble nonnative 
forms in the ER and decreased the rate of entry into the insoluble fraction, 
without altering secretion.  In parallel with these biochemical studies, the amount 
of ATZ recognized by a polymer-specific antibody also decreased upon UGGT1 
complementation (Figure 2.S2A-B).  The reason for solubility affecting trafficking 
of NHK and ATZ in different ways was not elucidated by this study, but likely 
involves different maturation pathways for the two proteins, possibly dependent 
on either retentive ER chaperone interactions and/or interactions with ER exit 
complexes.  
 Importantly, our results demonstrate from multiple independent 
approaches that UGGT1 requires its reglucosylation activity to promote NHK 
solubility.  First, castanospermine treatment—which blocks glucose removal from 
N-glycans and prevents the formation of unglucosylated N-glycan substrates for 
UGGT1—decreased UGGT1-mediated solubility.  Second, overexpression of a 
catalytically-inactive UGGT1 enzyme did not increase NHK solubility.  In contrast, 
NHK solubility was increased by expression of a chimeric UGGT1/UGGT2 
protein that contains the 20% carboxy terminal catalytic domain of UGGT2[16].  
Interestingly, although UGGT2 does not have reglucosylation activity in vitro, the 
chimeric protein harboring the catalytic domain of UGGT2 can function to 
promote substrate solubility (Figure 2.3A).  Lastly, UGGT1 had no effect on the 
solubility of NHK with all three N-glycosylation sites disrupted, which prevents 
formation of the UGGT1 substrate (Figure 2.6A-B).  
 To characterize the eventual fate of NHK molecules in the soluble and 
insoluble fractions, we performed 6 h chase after 24 h labeling experiments.  
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Interestingly, insoluble NHK was quite stable over a 6 h chase, and actually 
increased in amount with time in the absence of UGGT1, with soluble molecules 
entering the insoluble fraction (Figure 2.4A-B).  Theoretically, the amount of NHK 
in the insoluble fraction after 24 h is determined by three processes: 1) entry from 
the soluble fraction, 2) degradation of insoluble forms, or 3) solubilization of 
insoluble forms to enter the soluble fraction.  Interestingly, monoglucosylated 
NHK was not detected in the insoluble fraction (Figure 2.3D), indicating that 
UGGT1 cannot reglucosylate molecules that have entered the insoluble fraction, 
and therefore UGGT1 may not promote actual re-solubilization.  However, we 
cannot rule out the possibility that insoluble molecules that are reglucosylated 
may immediately re-enter the soluble fraction, and thus are not detected in the 
insoluble fraction based on jack-bean alpha-mannosidase digestion.  Another 
possibility for the absence of monoglucosylated NHK in the insoluble fraction—
based on a previous finding that NHK is found in ER subcompartments called 
inclusion bodies[50]—is that NHK may be physically sequestered away from 
UGGT1.  Lastly, perhaps the insoluble NHK forms a tight aggregate such that the 
recognition site for UGGT1 is not exposed. 
 Since ERAD is thought to require soluble substrates for degradation[51], 
the finding that UGGT1 promotes glycoprotein solubility could have implications 
for the degradation of glycoproteins in the ER.  Indeed, upon ERAD inhibition with 
kifunensine, total soluble NHK increased, and this effect was most prominent 
when UGGT1 was present (Figure 2.5A-C).  Insoluble NHK also seemed to 
increase upon ERAD inhibition, presumably due to the greater amount of soluble 
NHK available for entry to the insoluble fraction (although we cannot rule out that 
kifunensine may directly inhibit degradation of insoluble NHK).   
Another finding from this study involves the contribution of the three N-
glycans of NHK to its solubility.  First, we found that although solubility of NHK 
did increase directly by adding hydrophilic N-glycans to the polypeptide, a major 
fraction of this solubilization was UGGT1-dependent (Figure 2.6A-B).  This 
indicates that, at least for NHK, UGGT1-mediated reglucosylation contributes to 
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substrate solubility, in addition to solubility afforded by adding hydrophilic N-
glycans to the hydrophobic polypeptide.  CRT knockdown greatly decreased 
NHK solubilization in response to UGGT1 enzymatic activity (Figure 2.8C-E).  
From this, we infer that this UGGT1-dependent solubilization effect is due to 
reassociation with CRT/CNX, and is not a direct contribution from the glucose 
added to the N-glycan A-chain. 
The CNX cycle hypothesis[49] proposes that UGGT1 reglucosylates 
nonnative glycoprotein folding intermediates and promotes their reassociation 
with CRT/CNX for further folding attempts.  We directly tested how BiP interaction 
is involved in UGGT1-enhanced NHK solubility.  Indeed, we show that while the 
amount of soluble NHK increased with UGGT1 overexpression, the amount of 
BiP bound to soluble NHK clearly decreased (Figure 2.7A-B).  This appears to be 
an example of BiP acting as a second level ER quality controller for glycoproteins 
when interaction with their primary set of chaperones is disturbed[15, 52].   
 The role of UGGT1 in glycoprotein trafficking is intimately linked with the 
lectin-like chaperones CNX and CRT[21].  Previous studies have implied that 
NHK does not interact with calreticulin[53, 54]; however, we found that NHK 
extensively associates with CRT in Uggt1-/- MEFs cotransfected with NHK and 
UGGT1 (Figure 2.8A).  siRNA-mediated CRT knockdown strikingly reduced the 
ability of UGGT1 to increase NHK solubility (Figure 2.8C-E).  The fact that >99% 
of intracellular CRT resides in the soluble fraction (data not shown) presumably 
explains its ability to promote the solubility of monoglucosylated NHK.   
The exact mechanisms governing protein solubility and quality control in 
the ER are incompletely understood, but this study highlights how the ER 
enzyme UGGT1 can improve glycoprotein quality control by promoting solubility 
of glycoprotein substrates that are prone to misfolding (Figure 2.9).  Our results 
contribute to the CNX cycle theory by demonstrating that UGGT1-dependent 
lectin interaction can increase glycoprotein substrate solubility in the ER.  Further 
studies on the effect of glycan modifications and chaperone interactions should 
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provide additional clues to the mechanism(s) of maintaining solubility of 
glycoproteins during ER folding.  
 
2.4  Materials and methods 
 
Reagents and Antibodies  
Castanospermine was from Tocris Bioscience. Kifunensine was from Cayman 
Chemical.  Protein A-Sepharose, 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate hydrate (CHAPS), N-ethylmaleimide (NEM), 
phenylmethanesulfonyl fluoride (PMSF), leupeptin, antipain, pepstatin A, dithiobis 
succinimidyl propionate (DSP), and jack-bean alpha-mannosidase (JBM) were 
from Sigma.  Chymostatin was from VWR.  Endoglycosidase H (EndoH) and 
PNGaseF were from New England Biolabs.  Rabbit anti-AAT antibody was from 
DAKO.  Mouse mAb anti-KDEL and rabbit anti-CNX (used for immunoblotting) 
were from Enzo Life Sciences.  Rabbit anti-CRT was from Thermo Scientific.  
Rabbit mAb anti-GAPDH was from Cell Signaling.  Rabbit anti-BiP was from P. 
Arvan.  Rabbit anti-CNX (used for IP) antibody was a kind gift from A. Helenius.  
Rabbit polyclonal anti-UGGT1 antibody was a kind gift from A. Parodi.  Mouse 
monoclonal anti-antitrypsin polymer antibody (2C1) was a kind gift from E. 
Miranda and D. Lomas.     
 
CDNAs and Constructs  
NHK and ATZ mutant constructs were made by QuikChange mutagenesis 
(Stratagene) from wt-AAT in pcDNA3.1 using standard methods.  wt-AAT, NHK, 
and ATZ constructs were modified by S. H. Back to express AAT and EGFP as 
two separate proteins from a single mRNA by CAP-dependent and IRES-
dependent translation.  UGGT1 and variants were previously published[16].  NHK 
N-glycosylation site mutants were constructed using the QuikChange Lightning 
Multi Site-Directed Mutagenesis Kit (Stratagene).   
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Cell Culture 
Uggt1-/- MEFs[15] were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco) supplemented with 10% FBS and glutamax (Gibco).  Cells were 
cultured at 37°C in a 5% CO2 incubator.   
 
Steady-State Metabolic Labeling/Pulse-Labeling Analysis 
Uggt1-/- MEFs were transiently transfected using Lipofectamine 2000 transfection 
reagent (Life Technologies) with AAT constructs and either UGGT1 (1:3 molar 
ratio AAT:UGGT1) or an equal microgram amount of empty vector (pEDΔC).  The 
next day, cells were trypsinized and plated in separate 6-well plates, for pulse-
labeling or steady-state analysis.  Complete media supplemented with 0.1 mCi/ml 
[35S]-methionine and [35S]-cysteine (Tran35S-label, MP Biomedicals), was added 
to steady state wells 24 h post-transfection, and media and cells were collected 
48 h post-transfection (steady-state labeling).  Cells in the remaining wells were 
starved for 20 min in media lacking met/cys, pulsed for 20 min with starvation 
media supplemented with 0.1 mCi/ml [35S]-met/cys, and collected in the same 
manner as for steady-state labeling (next paragraph).   
 For each well, media was collected on ice, centrifuged at 10,000 X g for 10 
min at 4°C, and this cleared supernatant was called the extracellular fraction.  
Cells were lysed in 550 μl 2%CHAPS/HBS (50 mM HEPES, 200 nM NaCl) pH 
6.8 plus 200 mM PMSF, 20 mM NEM, and protease inhibitors (10 μg/ml final 
conc. chymostatin, leupeptin, antipain, and pepstatin A) for 20 min on ice.  Cells 
were scraped from the wells with a rubber policeman and lysate was transferred 
to a centrifuge tube.  Then, 100 μl lysis buffer was used to wash the well (to 
collect as much cellular material as possible), and this wash was added to the 
same centrifuge tube.  Lysates were centrifuged at 10,000 X g for 10 min at 4°C, 
and the supernatant was transferred to a new tube and called the soluble 
fraction.  Pellets from this centrifugation step were washed with 150 μl lysis 
buffer, centrifuged at 10,000 X g for 10 min at 4°C, and then the wash was 
removed.  Pellets were then solubilized by addition of 100 μl 1% SDS, sonicated, 
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and boiled at 95°C for 5 min.  1 ml 1% Triton X-100 was added to the pellet/SDS 
mixture, followed by centrifugation at 10,000 x g for 10 min at RT.  Unless 
indicated otherwise, equal proportions of each fraction were used for 
immunoprecipitation. 
 
Pulse-Chase Analysis 
Uggt1-/- MEFs were transfected as for steady-state labeling, but the starvation, 
pulse, and chase were performed 24 h after transfection.  Preparation of soluble 
and insoluble fractions, and double anti-AAT immunoprecipitation were similar to 
steady-state labeling analysis, but samples were not subjected to PNGaseF 
digestion. 
 
Immunoprecipitation/Gel Electrophoresis 
Trichloroacetic acid (TCA)-normalized volumes of extracellular, soluble, and 
insoluble fractions were incubated at 4°C o/n with anti-AAT antibody plus Protein 
A-sepharose.  Beads were washed 3x with ice-cold 0.5% CHAPS/HBS pH 7.4, 
and then the wash was removed completely by careful aspiration with a small-
bore pipette tip. To reduce background, antigen-antibody complexes were 
disrupted using the previously described 1% SDS/1% Triton X-100 resuspension 
method, and 1 ml of this supernatant was then incubated o/n at 4°C with anti-
AAT antibody plus Protein A-sepharose, then washed and dried by aspiration 
(double IP).  In most cases, beads were then subjected to PNGaseF digestion for 
1 h, then 3 μl 5x sample buffer plus dithiothreitol (DTT) was added, and this bead 
suspension was boiled at 95°C for 5 min.  Bead supernatants were analyzed by 
SDS-PAGE on 10% Tris-HCl Criterion gels or Mini-PROTEAN gels (Bio-Rad) at 
200 V for 40 min.  Gels were then Coomassie stained, destained, and dried in a 
gel-vacuum dryer for 2 h at 80°C. Finally, dried gels were exposed to a phosphor 
screen o/n and imaged on a Typhoon imager (GE Healthcare) and bands 
quantified with ImageQuant (GE Healthcare).  
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Dithiobis Succinimidyl Propionate (DSP) Crosslinking 
At 48 h post-transfection, NHK transfected cells were crosslinked in 2 mM DSP in 
4% DMSO/96% PBS for 30 min at RT.  Soluble and insoluble fractions were 
prepared and TCA-normalized volumes were subjected to anti-AAT double IP, 
and analyzed by reducing SDS-PAGE (breaks DSP crosslink).   
 
BiP-Luciferase Assay 
ER stress response was measured 48 h post-transfection using BiP-Luciferase 
expression plasmid[55], and a Dual-Luciferase Reporter Assay System 
(Promega), and a parallel set of wells were steady-state labeled to determine 
total intracellular AAT in each transfection group. 
 
Immunofluorescence  
Uggt1-/- MEFs were transfected with ATZ +/- UGGT1 cotransfection, plated on 
chamber slides, and fixed with 4% paraformaldehyde solution 48 h post-
transfection.  Cells were permeabilized and blocked in blocking buffer (1% BSA, 
0.1% Triton X-100, 0.01% NaN3 in PBS) for 1 h, and incubated o/n with 2C1 
culture media supernatant (CMS) (1:10) and anti-AAT antibody (1:1000) in 
blocking buffer.  Secondary antibody (Alexa 350, 555 (1:1000); Invitrogen) 
incubation was at RT for 1 h.  Slides were imaged on an Olympus FV500 
confocal microscope with Fluoview software (Olympus).  Z-stack analysis was 
performed using Metamorph software (Molecular Devices).   
 
siRNA Knockdown Experiment 
Uggt1-/- MEFs were transfected with Lipofectamine RNAiMAX transfection 
reagent (Life Technologies) at 0 h with either an equal mixture of two non-
overlapping CRT siRNAs (Silencer Select, Life Technologies), or non-targeting 
Negative Control No. 1 siRNA, at a 10 nM final concentration in transfection 
media.  Each transfection group was then transfected with Lipofectamine 2000 at 
48 h with DNA expression plasmids plus the same siRNAs as the 0 h 
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transfection.  Cells were trypsinized and split into two groups.  One group was 
steady state labeled from 72-96 h, and the other group was collected for 
immunoblot analysis at 96 h. 
 
Statistical Analysis 
Using Prism software (Graph Pad Software), Student’s t-test was used 
throughout. 
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2.6  Figures 
 
Figure 2.1  UGGT1 increases the solubility of alpha-1 antitrypsin mutants: 
NHK and ATZ   
A, B, C) 24 h metabolic labeling of Uggt1-/- MEFs transfected with (A) NHK, (B) 
ATZ or (C) wt-AAT +/- UGGT1 cotransfection.  Uggt1-/- MEFs were transfected 
with expression vectors encoding the misfolded alpha-1 antitrypsin variants null 
Hong Kong (NHK), the Z allele (ATZ), or wild-type AAT (wt-AAT), and 
cotransfected with either empty vector or UGGT1 expression vector.  Cells were 
radiolabeled from 24 to 48 h post-transfection in complete media plus 10 μCi/ml 
[35S]-methionine/cysteine.  Extracellular, soluble and insoluble fractions were 
produced (Experimental Procedures) and TCA-precipitation normalized volumes 
of each fraction were subjected to double anti-AAT quantitative 
immunoprecipitation and PNGaseF digestion, and analyzed by reducing SDS-
PAGE and autoradiography.  Substrate solubility was calculated by dividing total 
soluble (extracellular+intracellular soluble) substrate amount by insoluble 
substrate amount. Student’s t-test was used for statistical testing of the center 
panels, and paired Student’s t-test was used for statistical testing of the right-
most panels (* = p≤0.05). Error bars represent standard error of the mean (SEM).  
For ATZ: All UGGT1+ bands darkened with imaging software to make synthesis 
(data not shown) +/- UGGT1 appear equal.  
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Figure 2.2  NHK and ATZ, but not wt-AAT, become insoluble over time   
A)  Transient transfection of Uggt1-/- MEFs with wt-AAT +/- UGGT1 and analysis 
by pulse-chase at the indicated time points (Experimental Methods).  No wt-AAT 
was detected in the insoluble fraction at any time point.  B) same as A for ATZ.  
Here, ATZ progressively accumulates in the insoluble fraction over time.  C) 
same as A for NHK.  Here, NHK progressively accumulates in the insoluble 
fraction over time.  Soluble NHK was run on a non-reducing gel because under 
reducing conditions, the reduced IP antibody physically pushes all NHK bands 
down to the same molecular weight.  For A, B and C, four times the TCA-
normalized amount of insoluble fraction was used for IP, compared to soluble 
fraction (actual relative amount of insoluble ATZ and NHK is 25% of what is seen 
in the gel image).  D)  EndoH digest of extracellular, soluble and insoluble NHK, 
after steady-state labeling.  The majority of extracellular NHK is EndoH-resistant, 
evidence of having Golgi-modified N-glycans typically found on secreted 
glycoproteins.  NHK in the soluble and insoluble fractions is completely EndoH-
sensitive, indicating that these forms are not modified by Golgi-localized N-glycan 
modifying enzymes.  
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Figure 2.3  UGGT1 promotes solubility of NHK through monoglucosylation 
activity 
A)  Cotransfection with NHK and UGGT1 engineered variants and analysis of 
NHK.  After 24 h metabolic labeling in the presence or absence of glucosidase 
inhibitor castanospermine, total soluble/insoluble ratios of NHK were determined.  
An increased total soluble/insoluble ratio was observed only when UGGT1 
reglucosylation activity was expected, and this effect was blocked by glucosidase 
inhibition.  Error bars represent SEM.  B)  Estimate of the proportion of soluble 
NHK associated with CNX in the various experimental conditions from A.  
Soluble material was subjected to anti-CNX/anti-AAT antibody tandem IP and 
anti-AAT antibody double IP.  Appreciable NHK was only detected after anti-
CNX/anti-AAT tandem IP when UGGT1 reglucosylation activity and 
monoglucosylated substrate was expected.  C)  Cartoon of Jack-bean alpha-
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mannosidase (JBM) and UGGT1 activity.  D)  JBM digestion of N-glycans on 
NHK immunopurified from 24 h labeled soluble and insoluble fractions.  Bands 
corresponding to monoglucosylated or unglucosylated N-glycans are as 
indicated.  Soluble and insoluble fractions were run on the same gel, but 
insoluble bands were darkened with imaging software to appear similarly dense 
to soluble bands. 
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Figure 2.4  UGGT1 maintains increased total soluble/insoluble ratio for 
NHK during 6 h chase after 24 h labeling  
A)  24 h labeling and chase analysis of NHK.  After 24 h labeling, cells were 
chased with unlabeled media for 3 or 6 h, then extracellular, soluble, and 
insoluble fractions were subjected to anti-AAT double IP.  The amount of newly-
synthesized NHK recovered from a 20 min pulse-labeling was used to quantify 
NHK synthesis.  B)  Total amount of NHK remaining in each fraction after chase, 
normalized to synthesis.  Error bars represent SEM.  C)  Plot of total 
soluble/insoluble NHK at 0, 3, and 6 h chase point.  Student’s t-test was used for 
statistical testing (* = p≤0.05).  Error bars represent SEM.  
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Figure 2.5  ERAD inhibition increases UGGT1-dependent NHK solubility 
A)  Effect of kifunensine on intracellular NHK.  After cotransfection with NHK and 
UGGT1, 24 h metabolic labeling, and treatment with the mannosidase inhibitor 
kifunensine, amounts of NHK in extracellular, soluble and insoluble fractions 
were determined.  Amount of newly-synthesized NHK recovered from a 20 min 
pulse-labeling was used to quantify NHK synthesis.  B)  Quantification of NHK in 
extracellular, soluble and insoluble fractions, normalized to synthesis.  Error bars 
represent SEM.  C)  Total soluble NHK from B, with UGGT1 cotransfection, with 
and without kifunensine treatment.  Error bars represent SEM.  D)  Pulse-chase 
experiment demonstrating effect of kifunensine to limit degradation of soluble 
NHK when UGGT1 is present.          
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Figure 2.6  UGGT1-mediated solubility of NHK requires N-glycan on NHK   
A)  Analysis of NHK N-glycosylation mutants in transfected Uggt1-/- MEFs.  
Uggt1-/- MEFs were transfected with expression vectors encoding NHK N-
glycosylation site mutants with all combinations of the three N-glycosylation sites 
mutated [(Asp(N) to Gln(Q); 1. NHK-N46,83,247QQQ, 2. NHK-N83,247QQ, 3. 
NHK-N46,247QQ, 4. NHK-N46,83QQ, 5. NHK-N247Q, 6. NHK-N83Q, 7. NHK-
N46Q], cotransfected with either empty vector or UGGT1 expression vector, and 
subjected to steady-state labeling analysis.  B)  Quantification of three replicates 
of experiment in A.   A significant portion of the increased solubility of NHK with 
increasing numbers of N-glycans added is due to UGGT1 reglucosylation activity. 
Student’s t-test was used for statistical testing (* = p≤0.05).  Asterisks directly 
above bars indicate a significant difference in total soluble/insoluble ratio 
between that bar and non-glycosylated NHK (NHKQQQ), either with or without 
UGGT1 cotransfection.  Error bars represent SEM.  
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Figure 2.7  UGGT1 cotransfection reduces NHK association with BiP and 
reduces expression from the BiP promoter 
A)  Amount of BiP associated with NHK determined by immunoblotting of soluble 
material from DSP-crosslinked Uggt1-/- MEFs—with or without UGGT1 
cotransfection—with anti-BiP or anti-AAT antibodies.  B)  Quantification of three 
replicates of experiment in A.  UGGT1 cotransfection reduces the amount of BiP 
associated with NHK per molecule.  Error bars represent SEM.  C)  BiP-
Luciferase response to transient transfection of NHK or wt-AAT is reported 
normalized to total intracellular (soluble+insoluble) amount of AAT.  Tunicamycin 
treatment (6 h, 5 μg/ml) was included in cells transfected with AAT as a control 
for UPR activation.  Student’s t-test was used for statistical testing (* = p≤0.05).  
Error bars represent SEM.  
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Figure 2.8  Calreticulin (CRT) siRNA knockdown reduces UGGT1-mediated 
increased solubility of NHK  
A)  Tandem anti-AAT/anti-CRT IP of soluble material from Uggt1-/- MEFs 
cotransfected with NHK and UGGT1 and treated with or without DSP 
crosslinking.  The results demonstrate association between NHK and CRT.  B)  
Effect of CRT knockdown on chaperone expression.  CRT siRNA transfection 
greatly reduces the amount of CRT protein without any compensatory increase in 
CNX, BiP or GRP94 protein.  C)  Steady-state labeling analysis of Uggt1-/- MEFs 
transfected with CRT or NegCtrl siRNAs, and cotransfected with NHK and either 
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UGGT1 or empty vector (Experimental Methods).  D)  Quantification of C, each 
fraction represented as proportion of total.  E)  The effect of UGGT1 on the total 
soluble/insoluble ratio of NHK upon CRT knockdown.  Student’s t-test was used 
for statistical testing (* = p≤0.05). Error bars represent SEM.   
  
! 62!
 
 
 
Figure 2.9  UGGT1 promotes solubility of glycoproteins through promoting 
interaction with CNX and CRT   
Model depicts the role of UGGT1 in promoting solubility of glycoproteins through 
directing interaction with CNX and CRT.  Monoglucosylated NHK is not observed 
in the insoluble fraction, but only in the soluble fraction in association with CRT 
and CNX. 
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Figure 2.S1A  The anti-alpha-1 antitrypsin (AAT) immunoprecipitation (IP) is 
almost 100% efficient   
Equal fractions of cell media, soluble and insoluble fractions were pooled and 
subjected to one o/n immunoprecipitation (IP) with anti-AAT and Protein A-
sepharose.  Then, this IP supernatant was collected, remaining beads were 
washed 3X and resuspended with the 1% SDS/1% Triton X-100 method, and 
both the IP supernatant and SDS/Triton mixture were subjected to another round 
of anti-AAT IP.  There was little to no AAT found in the IP supernatants. 
 
Figure 2.S1B  NHK is found in the insoluble pellet from three different non-
ionic detergent lysis buffers 
Equal fractions of soluble and insoluble fractions from cells lysed in CHAPS (2% 
w/v); Nonidet P-40 (1% v/v); or Triton X-100 (0.5% w/v) and sodium deoxycholate 
(0.5% w/v) were subjected to double IP with anti-AAT and Protein A-sepharose.  
Similar amounts of NHK were found in all three insoluble fractions.   
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Figure 2.S2A  The 2C1 mAb recognizes ATZ polymers 
Uggt1-/- MEFs were transfected with ATZ with or without UGGT1 
complementation, fixed at 48 h post-transfection, and immunostained with anti-
AAT and the polymer-specific mAb 2C1.  Bar, 10 μm.  
 
Figure 2.S2B  2C1/ATZ ratio is reduced with UGGT1 cotransfection 
The ratio of 2C1 mAb to polyclonal anti-AAT immunofluorescence in individual 
cells was quantified (Metamorph software), using Z-stack imaging to account for 
any difference in microscopic depth of the respective subcompartments in which 
ATZ accumulates.  Cytoplasmic GFP co-expressed after an internal ribosomal 
entry sequence was used to define the full three-dimensional volume of each cell 
examined.  Student’s t-test was used for statistical testing (* = p≤0.05).  Error 
bars represent SEM.  
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Figure 2.S3  Enhanced intracellular solubility of ATZ correlates with the 
presence of enzymatic UGGT1 monoglucosylation activity 
After cotransfection with ATZ and UGGT1 engineered variants, 24 h metabolic 
labeling, and treatment with the glucosidase inhibitor castanospermine, total 
soluble/insoluble ratios of ATZ were determined.  An increased total 
soluble/insoluble ratio was observed only when UGGT1 reglucosylation activity 
was expected, and this effect was blocked by glucosidase inhibition.  Error bars 
represent range.  
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Figure 2.S4  UGGT1 engineered variants are expressed at comparable 
levels in Uggt1-/- MEFs 
Uggt1-/- MEFs were transfected with expression vectors encoding UGGT1, 
ΔUGGT1, and UGGT1/UGGT2, and subjected to steady-state labeling analysis.  
Expression levels were determined by double anti-UGGT1 immunoprecipitation.  
Error bars represent SEM. 
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Chapter 3 
Conclusions 
 
3.1 Introduction 
 
Protein folding in the endoplasmic reticulum (ER) is an orchestrated 
process, where a variety of resident ER proteins assist with the correct folding of 
substrate proteins.  Molecular chaperones and folding catalysts facilitate the 
advancement of substrate proteins towards a native folded state, without 
becoming engaged in the final structure of the substrate[1, 2].  The presence of 
chaperones and the extremely high protein concentration in the ER limits the 
ability of in vitro protein folding studies to accurately reflect protein folding within 
the ER environment[3].  Chaperone function results in protein folding assistance 
by limiting the formation of incorrectly folded ‘off-pathway’ structures, thereby 
improving kinetics of appearance of ‘on-pathway’ intermediates that lead to the 
native state[2].  Protein aggregates are examples of incorrectly folded ‘off-
pathway’ structures, and experiments have shown that molecular chaperones 
can reduce the propensity of substrate proteins to aggregate, both in vitro and in 
cells[2].   
Protein aggregates are medically relevant, as they are thought to play a 
pathogenic role in multiple human disease states, including neurodegenerative 
diseases and alpha-1 antitrypsin (AAT) deficiency.  These aggregates can be 
experimentally detected as insoluble species in cell lysis buffers based on 
nonionic detergents.  Such aggregates can easily reach both a large size and 
density, and can often be isolated merely by centrifugation, to separate crude cell 
lysates into soluble supernatant and detergent-insoluble pellet fractions.  I have 
! 72!
utilized this simple, reproducible method to study the role of UGGT1 in 
maintaining solubility of glycoproteins in the ER, using wild-type AAT and two 
misfolded AAT variants as model glycoproteins.  The Z allele (ATZ) variant has a 
single missense mutation (K342E) that results in formation of insoluble ordered 
polymers in hepatocytes, and this has been observed both in vivo and in cell 
culture[4].  The null Hong Kong (NHK) variant harbors a nonsense mutation that 
leads to truncation of the carboxy terminus of the protein[5].  NHK also becomes 
insoluble in cells, however, its truncation precludes ordered polymer formation.  
Instead, it is thought that insoluble NHK forms disordered protein aggregates[6].  
In contrast, wt-AAT forms neither ordered polymers nor disordered aggregates, 
and cannot be detected as an insoluble species under normal conditions.  One 
feature shared between wild-type AAT, ATZ, and NHK is that they each contain 
three N-linked glycans.   
Processing of N-linked glycans on glycoproteins in the ER is an intricate 
process that is critical for maintaining homeostasis of the glycoproteome, 
including folding, trafficking, and disposal of distinct components.  UDP-
glucose:glycoprotein glucosyltransferase (UGGT1) is central to these processes. 
As a critical component of glycoprotein ER quality control (ERQC), UGGT1 acts 
as a ‘folding sensor’, specifically reglucosylating intermediates in glycoprotein 
folding.  This activity is required for lectin-like reassociation with ER chaperones 
calreticulin (CRT) and calnexin (CNX), which for some glycoprotein substrates 
can assist in additional folding attempts, for other substrates can promote export 
from the ER, and for yet other substrates may either limit or promote ERAD[7].  A 
central idea conveyed by this dissertation is that promotion of glycoprotein 
interactions with lectin-like ER chaperones assists in keeping these substrates in 
a soluble state, which is necessary for delivery of these substrates to their 
respective biological fates.  In contrast, defects in the reglucosylation of N-linked 
glycoprotein substrates, and impaired interaction with lectin-like ER chaperones, 
may enhance formation of insoluble glycoprotein aggregates.  Almost certainly, 
this is a problem for the cell, leading to specialized coping mechanisms, including 
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sequestration, degradation, and possibly resolubilization, of such aggregates.  
Failure of such mechanisms may underlie proteotoxicity, and prevention of 
insolubility is likely to enhance cell survival.  The effect of UGGT1 on the 
solubility, folding, and delivery of glycoprotein substrates may well explain why 
UGGT1 is essential for embryo survival, as there is reason to believe that failure 
of reglucosylation underlies severe placental vascular insufficiency, which may 
be responsible for the embryonic lethal phenotype of Uggt1-/- mice at E13 
(Figure 3.1).  The other components of the calnexin cycle are also essential for 
mammalian development, as whole-body genetic deletion of CRT, CNX, and 
ERp57 in mice results in embryonic or perinatal lethality[8-10]. 
To study the effect of UGGT1 on solubility of NHK and ATZ, Uggt1-/- MEFs 
transiently expressing these substrates, in the presence or absence of UGGT1 
complementation, were labeled with [35S]-methionine/cysteine to approach 
steady state.  This long-term labeling allowed for recovery of chemical quantities 
of substrate in three different pools: 1) secreted (extracellular), 2) intracellular 
soluble, and 3) detergent-insoluble.  Amounts of AAT substrates in each fraction 
were measured by quantitative anti-AAT immunoprecipitation (Chapter 2.4, 
Materials and methods).  To exclude differences in substrate protein expression 
(synthesis) between individual samples, each transfected sample was analyzed 
in parallel by short-term pulse-labeling, so that the steady state amounts 
recovered could be normalized to substrate synthesis from the same transfection.  
The actual experimental results have been described in Chapter 2; in this chapter 
I will highlight key findings and propose future studies that emerge from these 
findings.  
 
3.2  Similarities and differences in the effect of UGGT1 activity on ER 
trafficking of NHK and ATZ 
 
For both NHK and ATZ, the ratio of total soluble (extracellular+intracellular 
soluble)/insoluble substrate increases when UGGT1 is coexpressed.  UGGT1 
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cotransfection significantly shifts the pool sizes of both NHK and ATZ towards the 
soluble intracellular fraction (Chapter 2, Figures 2.1A, 2.1B).  However, closer 
inspection of the outcome for these two substrates reveals that UGGT1 
complementation shifts these pool sizes in different ways.  For NHK, UGGT1-
mediated enrichment of the intracellular soluble pool derives from a combination 
of decreased escape to the endoglycosidase H-resistant, extracellular (secreted) 
fraction (indicative of transport to and through the Golgi complex) and from  
decreased entry to the insoluble fraction (Figure 2.1A, middle panel; Figure 
2.4B).  For ATZ, the activity of UGGT1 promotes a decrease in the detergent-
insoluble fraction—that is thought to represent loop-sheet polymerized ATZ—but 
no change in ATZ secretion (Figure 2.1B, middle panel).  Thus, UGGT1 acts as 
an ERQC factor in both cases, enhancing solubility, but the consequences of that 
solubility are different for the two substrates.   
The mechanism(s) underlying the different consequences of UGGT1-
mediated reglucosylation on these two glycoprotein substrates is not clear, but it 
is likely to involve intrinsic differences in substrate folding states.  Consider that 
the two substrate pools, extracellular and insoluble intracellular, represent the 
end point of two different exit paths from the soluble intracellular pool.  Then, 
consider that UGGT1 acts as a folding sensor for molecules traveling on either of 
these two distinct pathways.  And finally, consider that UGGT1 has optimal 
recognition of near-native intermediate folding forms in comparison to other 
distinct folding forms on opposite ends of the folding spectrum, i.e., native or 
severely misfolded[11, 12].   
Thus, it is tempting to speculate that at ER exit sites, near-native (but 
nevertheless mutant) NHK molecules are recognized by UGGT1, reglucosylated, 
and returned to the ER pool through iterative interaction with CRT/CNX[13].  It is 
similarly tempting to speculate that NHK folding forms approaching the 
ERQC/ERAC compartment are badly misfolded, so that only a small percentage 
of these molecules can be recognized by UGGT1 and reglucosylated, limiting 
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ERAD.  Furthermore, I hypothesize that the majority of NHK molecules that are 
already engaged in protein aggregates are not recognized by UGGT1 at all.   
For ATZ, the situation might be that molecules delivered to ER exit sites 
appear as well-folded substrate such that they pass through the UGGT1-
mediated ERQC checkpoint (this idea is supported by the fact that exported ATZ 
has biological activity[14]), and once beyond the ER, ATZ is allowed to be 
secreted.  But the ATZ folding forms approaching the ERQC/ERAC—which could 
include small (dimer, trimer, oligomer) forms of ATZ—are recognized by UGGT1, 
reglucosylated, and returned to the soluble fraction, presumably via renewed 
interaction with CRT/CNX. 
Thus, I propose that the difference in UGGT1-mediated trafficking of NHK 
and ATZ is based on the folding status of subpopulations of each substrate when 
they encounter UGGT1.  However, I must acknowledge an alternative 
explanation, namely, that NHK expression causes ER stress and UPR activation 
whereas ATZ expression does not.  This could result in different amounts of ER 
chaperones in cells expressing the different substrates.  As a consequence, 
when NHK or ATZ molecules are reglucosylated by UGGT1 and associate with 
CRT/CNX, there could be different subsets of additional chaperones recruited to 
this complex, which could mediate decreased secretion or decreased 
polymerization, respectively.   
This alternative explanation would likely benefit from testing UGGT1-
mediated trafficking effects on other luminal ER glycoproteins, to determine if the 
trafficking differences between NHK and ATZ are limited to these two substrates 
or are a more general phenomenon.  The hepatic toxicity due to ATZ 
accumulation in alpha-1 antitrypsin disease has been suggested to be analogous 
to the brain toxicity caused by accumulation of neuroserpin mutants in the familial 
dementia known as FENIB (familial encephalopathy with neuroserpin inclusion 
bodies).  These mutant neuroserpins are ER luminal glycoproteins that form 
ordered polymers similar to those of ATZ and as such, could represent another 
good model for testing UGGT1-dependent trafficking changes[15].  For NHK, 
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another well-studied ER luminal substrate that is also glycosylated, but not 
thought to form ordered polymers, is an engineered soluble form of beta-site 
amyloid precursor protein-cleaving enzyme 1 (BACE)[16].  Studies on these and 
other model glycoprotein substrates would allow for an understanding of whether 
the differences in UGGT1-mediated trafficking of NHK and ATZ are unique to 
these two molecules.   
Finally, in my analysis, I assume that once these substrates are released 
to the media, they do not return to either intracellular pool.  Importantly, at the 
conclusion of pulse-labeling, the entirety of newly-synthesized NHK and ATZ 
begins in the soluble fraction.  Thus, over the course of time as iterative rounds of 
newly-made NHK and ATZ progress towards their steady state distributions, a 
fraction of these substrates must transition to the detergent-insoluble pool.  
However, it remains unknown if substrate from the insoluble pool can be 
resolubilized and return to the soluble pool.  Such a thing is possible, as there is 
precedent for aggregate dissolution, both in bacteria and in eukaryotic cells[17-
19].   
 
3.3  UGGT1 mediates a major fraction of the N-glycosylation solubility 
effect 
 
 Experiments with N-glycosylation site mutants of NHK demonstrate that a 
major portion of the solubility increase of NHK on N-glycan addition is UGGT1-
dependent.  Additionally, each of the NHK N-glycans contribute to solubility, and 
each provides a fairly similar contribution (Chapter 2, Figure 2.6).  These results 
are analogous to those found in a study of secretion of BACE variants with 
combinations of four N-glycosylation sites mutated; each of which showed similar 
effects[16].  One study showed that in isolated microsomes, two N-glycans in 
close proximity were necessary for efficient formation of monoglucosylated N-
glycans[20].  Both the study of BACEs and the present study of NHK N-
glycosylation mutants show that in cells, singly-glycosylated substrates can still 
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enter the calnexin cycle, strongly suggesting UGGT1-dependent 
monoglucosylation of solo N-glycans. 
 The finding relating N-glycan addition to substrate solubility may have 
important implications for strategies to improve secretion of protein therapeutics 
by adding new N-glycosylation sites into naïve sites[21, 22].  Studies to date that 
have used Sf9 insect cells to produce model substrates are concentrated on 
mainly Man3GlcNAc2 N-glycans—the major oligosaccharide form transferred by 
Sf9 OST—for which re-entry into the calnexin cycle is not possible, because they 
lack the terminal A-chain mannose necessary for UGGT1-mediated 
reglucosylation[23].  Although addition of novel N-glycosylation sites does 
increase glycoprotein stability and decrease propensity to aggregate in vitro, it is 
unclear what the effect of adding novel N-glycosylation sites to glycoproteins 
would have in the context of the CNX/CRT/UGGT1 ERQC system in mammalian 
cells. 
 
3.4  Future directions 
 
One of the challenges in the field of glycoprotein ERQC is forming general 
theories about trafficking from separate studies on disparate model proteins, as it 
has been shown repeatedly that different substrates can meet quite different 
fates in the same cell[24] and the same substrate can meet different fates in 
different cells[25].  This is especially apparent for our understanding of aggregate 
handling and degradation of ER glycoproteins.  A strategy used by Kopito’s group 
to understand cytoplasmic protein misfolding and aggregation made use of 
multiple substrates with different properties: 1) a mutant protein that misfolds at 
nonpermissive temperatures, 2) a protein subunit lacking its usual partner, and 3) 
amyloidogenic substrates[26].  Each of these substrates was tagged with a 
fluorescent label, conditionally expressed in cells, with intracellular localization 
followed by microscopy.  By expressing the different substrates simultaneously in 
the same cell, they were able to show that the amyloidogenic substrates 
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accumulated only in one cytosolic subregion (IPODs in which the substrates were 
largely immobile) while other misfolding substrates could accumulate in IPODs or 
another cytosolic subregion, the JUNQ compartment (in which the substrates 
underwent rapid exchange with the cytosol)[26].   
A similar strategy could be employed to better understand glycoprotein 
misfolding and aggregation in the ER.  Continuing with the same substrates used 
in this thesis, fluorescent tags could be added to NHK and ATZ, and then 
expressed using a conditional expression system to provide more control over 
the timing of expression than with transient transfection.  These two substrates 
could then be expressed in the same cells, and the fluorescent signal observed 
by microscopy to determine if the two substrates are accumulating in the same 
compartment, possibly the ERQC/ERAC compartment.  This experimental 
paradigm could then be manipulated with proteasome or autophagy inhibitors to 
determine whether blockade of either of these degradation pathways results in a 
build-up of substrate in any specific cytoplasmic location, or in the ER.  Also, the 
same method could also be used in Uggt1-/- MEFs with and without UGGT1 
cotransfection, to determine if UGGT1 affects the localization of these substrates 
in the ER, qualitatively and quantitatively.  Additionally, luminal, transmembrane 
or multi-subunit proteins could be utilized here, as well as proteins with N-
glycosylation sites mutated.        
 
3.5  Closing remarks 
 
 Production of correctly folded glycoproteins is a highly regulated process, 
centered on modification and recognition of protein bound N-glycans.  In this 
thesis, I have shown that the folding sensor enzyme UDP-glucose:glycoprotein 
glucosyltransferase (UGGT1) plays a critical role in this process for two misfolded 
alpha-1 antitrypsin variants, NHK and ATZ.  Importantly, I have provided 
evidence that at least for NHK, simple addition of N-glycans to the protein 
provides some increased solubility, but engagement of the calnexin cycle 
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chaperone system by UGGT1 maximizes solubility.  UGGT1-mediated 
monoglucosylation of these substrates appears to play a significant role in 
enhancing intracellular protein solubility, as detergent-insoluble fractions were 
found to completely lack monoglucosylated glycans.  These findings and further 
studies of glycoprotein ERQC should help us to better understand ER storage 
diseases like alpha-1 antitrypsin deficiency, and produce new therapeutic 
avenues for treatment.  
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3.6 Figures 
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Figure 3.1  Vascular insufficiency in Uggt1-/- placenta 
Hematoxylin and eosin (H&E) staining of placental sections associated with 
E11.0 Uggt1+/+ or Uggt1-/- mouse embryos.  The labyrinthine region of Uggt1-/- 
placenta is small and underdeveloped, with a significant reduction in fetal blood 
vessels, observed through specific lack of nucleated fetal red blood cells. 
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